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I. Introduction and summary of key outputs 
Context 
The 2011 work programme takes forward activities begun in 2010 to implement the EMCDDA’s three-year 
strategy (2010–12). Key themes of this strategy are the consolidation of core data, investment in more 
complex and policy-relevant analysis, and the development of a small number of new areas of strategic 
importance. Progress was made in all these areas in 2010, and this document details the next steps to be 
taken.  
Although providing continuity is a central objective for work in 2011, the EMCDDA recognises that its 
activities do not take place in a vacuum and that it must be ever mindful of factors that can impact, positively 
or negatively, on its ability to fulfil its mandate. For this reason, the work programme is forward-looking, 
introducing or scaling up some activities where it has become apparent this is required. In part, this is 
prompted by the rapidly evolving nature of the drug situation and the lessons learned from work in 2010.  
Changes to the internal organisation of the EMCDDA will have implications for activities in 2011 as new 
structural arrangements are established. With regard to external factors, there is the need to be responsive 
to emerging opportunities or critical information requirements. During 2010, the EMCDDA was able to better 
coordinate some developmental activities with programmes of the European Commission and this has had a 
positive knock-on effect on the achievements possible in 2011. In particular, this will have a positive impact 
on the development of key indicators in the area of supply reduction and the identification and promotion of 
good practice in the area of health and social responses to drug problems. Additionally, the information 
needs for the evaluation of the current EU drugs strategy and action plan are now clear and the 2011 work 
programme has been configured to reflect these important information needs.    
The EMCDDA’s achievements are only possible through partnership with national data providers and 
experts as well as with relevant EU bodies and international organisations. The agency is committed to 
developing effective working partnerships with appropriate European and international agencies and this is 
reflected in the work programme. It is essential to mention here the importance of the Reitox network of 
national focal points who act as the main interface between national data collection and expertise and the 
EMCDDA. We acknowledge that Reitox support and input is a prerequisite for accomplishing a large 
proportion of the tasks set out below, including new developments in supply reduction and best practice. The 
difficult economic situation has resulted in pressure on the public purse across the EU and many focal points 
are facing difficult funding situations. Moreover, funds available for investment in data collection activities are 
likely to be restricted in the coming year. The EMCDDA will remain in close dialogue with focal points on 
these issues and seek to assist them where this is possible.  
The resources required for implementing the 2011 work programme will be provided by the EMCDDA budget 
for 2011, as adopted by its Management Board, on the basis of the decision of the Budgetary Authority on 
the EC annual subsidy to the EMCDDA’s budget. The EC annual subsidy on which the 2011 EMCDDA 
budget relies is expected to amount to EUR 15 400 000. This planning exercise is drawn up on the basis of 
this estimate. Changes in the monies available to the EMCDDA to fulfil its mission would require adjustments 
to be made to the activities proposed here.   
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Summary of key outputs in 2011 and their intended audience  
 
Other target audiences Output Policy 
Science Practice  Citizen 
Annual report on the state of the drugs problem in Europe  
(printed, 23 languages) a a a a 
Selected issues 
- History, methods and implementation of national treatment 
guidelines 
- Cost of treatment  
- Mortality related to drug use: a comprehensive approach and 
public health implications  
(printed, EN with summary in 23 languages) 
a a a a 
Drugs in focus policy briefings  
- Responding to new psychoactive substances 
- Drug-related research  
- Khat 
- Minimum quality standards for drug demand reduction 
(printed, 25 languages) 
a    
EMCDDA Monographs 
- New groups of psychoactive substances in Europe  
(printed, EN with summary in 23 languages) 
a a   
EMCDDA Insights  
- Cannabis market and production in Europe 
- Heroin-assisted treatment 
- Understanding drug use in the context of models of dependency 
and compulsive behaviour 
(printed, EN with summary in 23 languages) 
a  a  
EMCDDA Manuals  
- Drug-related infectious diseases (DRID) protocol module 
- Mortality cohort protocol 
- European guidelines for the evaluation of national drug strategies 
(printed, EN) 
  a  
Joint publications 
EMCDDA−Europol joint publications 
- The European ecstasy market 
(printed, EN) 
a a a a 
ECDC−EMCDDA joint guidance on the prevention of infections 
among injecting drug users 
(printed, EN) a 
   
EMCDDA Risk assessments 
- Mephedrone 
 (printed, EN) a 
   
EMCDDA National drug policy profiles 
(new series to be launched in 2011) a    
EMCDDA website 
(online, EN, with some multilingual sections) a a a a 
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Other target audiences Output Policy 
Science Practice  Citizen 
Statistical bulletin  
(online, EN)  a a  
Country overviews (including situation summary, data sheet and 
barometer) 
(online, EN and national language) a 
 a a 
Drug profiles 
- Update of full set of drug profiles 
(printed, EN) 
- two new psychoactive substances (as appropriate) 
(online, DE, EN, FR) 
a a a a 
Best practice portal 
(online, EN) a a a  
Evaluation instruments bank (EIB) 
(online, EN) a  a  
European legal database on drugs (ELDD) 
(online, EN) a a a  
Research resources area 
(online, EN) a a   
Drugnet Europe newsletter 
(printed and online, EN, four issues) a a a a 
General report of activities  
(online, EN) a   a 
A detailed list of printed and online outputs (showing timing and relation to specific objectives) can be 
found in section II.2.
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II. Monitoring and reporting on the drugs problem in Europe: selected 
highlights in 2011 
Overview  
In 2011, monitoring and reporting work is presented in a more holistic structure reflecting the new 
organisation of scientific work within one scientific division. The tables found later in this section provide a 
comprehensive list of activities planned for 2011. An initial table describes the core business of information 
collection necessary for EMCDDA annual reporting. This is supported by supplementary tables that detail the 
different substantive areas of work: key epidemiological indicators, responses data, transversal analysis, 
supply and supply reduction activities, new trends and developments, drug policies and laws, and guidelines 
standards and best practice. The areas of inquiry for each of these information domains are set out in the 
three-year strategy and this document has been structured to facilitate cross-references to it (1). To aid 
clarity, a distinction is made between ongoing work and more developmental activities. Approaches vary in 
different areas and reflect what is currently feasible at a European level, the stage of development of the 
work and its level of priority. Activities for the supporting infrastructure — institutional and technical 
cooperation, communication, governance, management and networks and administrative and information 
technology support services — are set out in a similar way.  
Three core transversal goals lie at the heart of the agency’s mandate to provide factual, objective, reliable 
and comparable information on the European drug situation: 
 
1. Producing a state-of-the-art annual review of developments in drug use and responses in Europe situated 
within a broader explanatory conceptual framework (scientific, historical, demographical and socio-political). 
2. Maintaining an up-to-date and high-quality European reference point on drugs. 
3. Providing ongoing support to EU institutions and Member States for implementing and monitoring the EU 
action plan. 
 
Although it is easy to state these goals, achieving them is a complex and ongoing task that consumes a 
substantial proportion of the agency’s resources. These core activities are discussed in detail in the 2010–12 
work programme and included in the supporting tables. In the text below, we highlight some of the more 
unique, developmental activities planned for 2011, which give this year’s work programme its distinct flavour. 
A focus on core business — delivering value, and ensuring the European system remains fit for 
purpose 
At the heart of the European drug information system are the key epidemiological indicators (KI) that provide 
the framework for understanding the nature and scale of the European drug situation. The analytical value of 
this information comes from its longitudinal nature and we benefit today from efforts made over the life of the 
agency to develop and sustain these measures. Not only do the KI give us an overview of the current drug 
situation; they also provide elements necessary to address more complex analytical questions, such as the 
impact of supply reduction measures, whether responses are in line with needs, and whether policies are 
impacting on consumption levels. In the 2011 work programme, priority is given to the efficient collection and 
analysis of KI data and to maintaining the technical networks that sustain them. The following developmental 
activities are of particular note: the final stage in the rationalisation of the treatment demand indicator; the 
continued work to broaden the scope of the problem drug use indicator; and the update to the protocol for 
collecting information on infectious diseases. Building on successful experiences in 2010, we will continue to 
invest in working with decentralised databases to better exploit the available data and facilitate new analysis, 
and a new series of analysis workshops (‘data laboratories’) are planned.   
                                                     
(1) EMCDDA strategy and work programme 2010–12 (http://www.emcdda.europa.eu/html.cfm/index82061EN.html). 
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Of equal importance to monitoring the drug situation are the core instruments that allow the EMCDDA to 
report on responses made by Member States to the drug problem. Over the last 15 years, a number of 
instruments have been developed for this purpose and, despite some limitations, quality and coverage of 
data in this area has improved considerably. In 2010, an internal working group was launched with the 
purpose of reviewing how the responses indicators could be recast into a more conceptually coherent set of 
analytical tools. Based on these discussions, and within the context of the general framework for instrument 
development agreed with the Reitox network, further work is planned for 2011. Developments will focus on 
the different treatment dimensions, social reintegration and legal mechanisms. Where possible, and taking 
into account national data collection capacity, measures to improve the cost estimation of responses will also 
be added to the responses tools. 
A central consideration for the EMCDDA is to ensure that the reporting system remains relevant to European 
needs. To guarantee this, a top-level strategic review of the current reporting system will commence in 2011, 
which will span tools and approaches, analytical processes and outputs. A number of factors make 2011 an 
appropriate time for this strategic review, including the fact that the current phase of the Fonte project and 
the technical revision of reporting tools (a collaborative exercise with Reitox that started in 2006) have now 
been successfully completed.  
External factors that may have an impact on our work need to be considered in this review. These range 
from changes observed in the drug situation and policy landscape, to the possible implications of the new 
Lisbon treaty and organisational changes within the European institutions. In 2012, the EMCDDA will finalise 
a new three-year work programme (2013–15) that reflects the needs of the new EU drugs strategy. To 
ensure sufficient time for the consultation exercise, the drafting process will start in 2011. More generally, the 
EMCDDA faces the challenge of meeting growing information needs within a stable or reducing resource 
environment. To remain successful, the value accrued from the resources available must be maximised and 
our priorities must remain clearly defined and relevant to evolving European needs.    
Remaining responsive to developments 
In 2010, the EMCDDA had to respond to an increasingly dynamic situation with regard to emerging new 
drugs and a record number of new substances were reported through the early warning system (EWS) 
network. Continued consolidation and development of this area will remain important in 2011, which will see 
the launch of a more robust Internet monitoring strategy, more analytical linkage between the EWS and 
epidemiological reporting, and work to develop the forensic toxicology capacity within the current system. A 
key task will be to assist with and respond to the forthcoming European Commission assessment of the 
mechanism for the information exchange, risk assessment and control of psychoactive substances. The 
impact of this exercise is difficult to predict but is likely to require some reconfiguration of current practices. 
Other highlights include the release of a scientific monograph on developments in new drugs, the release of 
additional drug profiles and the organisation of the first trend-spotting meeting. Trend spotting provides a fast 
track tool for investigating potentially important new developments in drug consumption patterns.      
Identifying best practice and encouraging its uptake and further dissemination 
Understanding the drug problems Europe faces is a prerequisite to responding effectively. However, the 
EMCDDA also has a duty to identify and encourage the sharing and uptake of evidence-based practices — 
an area of growing importance. The recently re-launched Best practice portal provides decision makers and 
practitioners in Europe with up-to-date information on evidence-based interventions. In 2011, the scope of 
the tool will be expanded, taking into account results of studies carried out on behalf of the European 
Commission on minimum quality standards for demand reduction, with updated modules on treatment and 
harm reduction, and a new module on social reintegration. Interventions delivered in special settings such as 
prisons will also be included in the portal to present evidence for prevention, harm reduction and treatment 
provided under conditions that differ considerably from the outside world. Beyond ensuring the update of 
existing records, consideration will be given to improving how information is generated for the portal. 
The best practice area of work will benefit from ongoing improvements to the EMCDDA’s capacity to monitor 
and report on drug treatment. This is an area where internal capacity has been increased and where the 
agency has strived to improve its overall performance. A series of state-of-the-art treatment reviews are 
under development. The first set, to be released in early 2011, will provide a comprehensive review of recent 
clinical trials to assess the efficacy of heroin-assisted treatment and also explore the problems faced in 
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implementing this kind of intervention. A second set of reviews will be prepared on therapeutic communities 
and residential care facilities in the EU. Residential care has historically been an important component of 
treatment for opiate addicts in many countries and there is currently renewed interest in this treatment 
modality. Work will also commence on a state-of-the-art review of treatment for cannabis-related disorders. 
The provision of treatment for cannabis-related disorders has increased in Europe; however, there is no 
overall consensus on what constitutes appropriate models of care. This review is timely as it will benefit from 
growing experience in the EU of proving care for this group as well as emerging research evidence including 
results of a new European random control trial. This work will complement the epidemiological assessment 
of the level of cannabis-related problems.   
The combination of traditional reviews and paper-based publications with more comprehensive information 
provided in the Best practice portal will be further developed in 2011. User statistics and feedback from the 
field as well as the input and advice provided by the Scientific Committee will help improve this strategic area 
that is becoming central to the agency’s work. 
Collaboration and partnership  an organisational strength 
The EMCDDA is committed to working in close partnership with other European and international agencies 
and organisations. Not only does this avoid duplication of effort; considerable added value can be gained 
from combining expertise from different perspectives. Examples of this approach in the 2011 work 
programme include a joint product planned with the European Centre for Disease Prevention and Control 
(ECDC) which will provide guidelines on the prevention of infections among injecting drug users, and the 
preparation of new joint EMCDDA−Europol situation reports on the European market focusing on ecstasy 
and heroin.   
In 2010, the EMCDDA and the European Commission invested time in ensuring that their respective 
developmental activities on monitoring drug use complement one another. This has had a positive impact for 
2011 work in those areas where synergies were found to exist. With clear relevance for the Best practice 
portal, the EMCDDA is working with the European Commission to develop minimum quality standards for 
demand reduction activities. This work is supported by a research study that has been commissioned to 
provide an EU inventory of standards and guidelines for different types of interventions. A key aspect of this 
study is to develop a mechanism for building consensus on what constitutes minimum quality standards. 
This study will incorporate EMCDDA data and work closely with the Reitox network and EMCDDA staff. The 
findings will inform the agency’s future work and outputs.   
In 2011, the EMCDDA will also support the work of DG SANCO to prepare the analysis necessary for the 
second progress report on implementing the Council Recommendation on the prevention and reduction of 
health-related harm associated with drug dependence of 18 June 2003. The work to be undertaken is 
directly relevant to, and extends the scope of, activities to assess the implementation of harm reduction 
interventions across the EU. The project will benefit from and contribute to the ongoing monitoring of harm 
reduction interventions in Europe and will allow EMCDDA staff to share their expertise and work closely with 
external contractors. The inclusion of the EMCDDA as a project partner removes the possibility of duplication 
of effort.  
In 2010, with financial support from the European Commission, the EMCDDA started implementing a 
technical assistance project with candidate and potential candidate countries that will last until November 
2011. The aim of this project is to prepare the beneficiary countries for their future participation in the 
agency’s work. In parallel, it is expected that during 2011 technical cooperation will be gradually initiated with 
the countries covered by the European Neighbourhood Policy (ENP).  
The strategic document adopted by the EMCDDA Management Board in July 2009 on the ‘Implementation of 
the strategy for international cooperation’ sets out that the outcome of the cooperation should, as far as 
possible, be integrated into the EMCDDA knowledge base and data sets. This will be done in 2011 through: 
the publication of online country overviews, national reports and updated information maps produced within 
the framework of the IPA project; the dissemination of the joint handbook on building a national drugs 
observatory in Croatian, Turkish, Arabic and Russian; and the production of a thematic publication on ‘Drug 
supply reduction activities in candidate and potential candidate countries to the EU’. 
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As far as cooperation with regional and international organisations is concerned, the work on developing 
harmonised drug monitoring systems and data collection tools will continue in collaboration with WHO, 
UNODC and CICAD. In addition, the EMCDDA will support, as appropriate, the assessment of the UN 
declaration and plan of action. Further development of the Best practice portal and international comparisons 
of intervention standards will also require close collaboration with numerous external partners. 
Developing information resources in supply reduction  
The need to scale up the monitoring of supply reduction activities is an important component of the current 
EU action plan and the EMCDDA’s 2010–12 work programme, and this area has been given prominence in 
the agency’s new structure. In 2010, progress was made in building consensus on the key elements that 
constitute a more comprehensive monitoring system. A conference based on the results of EC-funded 
preparatory work and the EMCDDA’s experience was held in close collaboration with Europol to initiate work 
on the conceptualisation of sustainable key indicators in this area. In 2011, the consensus process will be 
taken forward in three substantive expert groups (drug markets, drug-related crime and drug supply 
reduction). These groups will prepare a proposal for new key indicators for monitoring drug supply issues to 
be debated in a second consensus-building meeting scheduled for the end of 2011.  
Support for the evaluation of the European drugs strategy and action plan  
The information needs of the EU strategy helped to shape the content of the 2010–12 work programme and 
the agency and the European Commission maintain a close, ongoing dialogue on this issue. This has 
resulted in an agreement for the EMCDDA to provide the European Commission by June 2011 a detailed 
time series analysis of changes in the EU drug situation since 2005. This analysis will also include a state-of-
the-art assessment on the implementation of key interventions and policies that are specified in the drugs 
strategy and its action plans. This additional analysis and reporting will extend the routine work planned for 
annual reporting in 2011, but the agency recognises the value of this task and the need to support this 
important exercise.  
Support for the external evaluation of the EMCDDA 
The European Commission will launch an external evaluation of the EMCDDA in 2011 to coincide with the 
completion of the three year work programme in 2012. The EMCDDA will provide support to the European 
Commission and the external evaluator.  
Methodological developments  focus on polydrug use and combined analysis  
A theme that will be developed in 2011 work is the need to move beyond a simple, substance-specific 
perspective and address polydrug use. The agency recognises the need to look at different types of 
addictions in a broader framework and an EMCDDA Insights on understanding drug use in the context of 
models of dependency and compulsive behaviour is planned for 2011. In addition, attention will be given to 
exploring the interaction between alcohol and drugs in recognition of the strong relationship between drug 
and alcohol use and their related problems. In this context, work will be continued and expanded (in close 
collaboration with relevant partners) on adult and youth population surveys to obtain a better understanding 
of the interactions between licit and illicit substances. An analytical workshop held in partnership with ESPAD 
is planned on polydrug use.  
Use of licit substances (such as medicines and alcohol) can interact with illicit drug use and in doing so 
impact on overall morbidity and mortality. In 2011, the EMCDDA will have more detailed information on 
substances (licit and illicit) present in overdose deaths and will initiate developmental work on the core 
national datasets of special mortality registries. With regard to the treatment demand indicator, analyses on 
clients entering treatment for use of stimulants, and the possible role of alcohol in worsening their drug 
problems are planned.  
Improved coordination of activities and a focus on policy-relevant analysis 
In 2010, the Management Board approved the Director’s proposal for reorganisation of the EMCDDA. This 
reorganisation aims to deliver greater coordination and common purpose to the scientific work of the agency. 
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From 1 October 2010, scientific teams have been brought into a single division and each unit’s 
responsibilities cover not only a substantive area but also transversal tasks. This structure reflects and 
supports the recognition that the value of much of the agency’s work comes from bringing together different 
data sources and expertise to address important policy questions and the need to increase transversal and 
multi-indicator analysis. The structure also enables us to increase the coherence and visibility of some areas 
of growing developmental importance mentioned in the recast to the EMCDDA’s founding regulation, 
notably: supply reduction; emerging trends, particularly those involving polydrug use; the monitoring of policy 
developments; and the identification and dissemination of best practice. In 2011, the new teams and 
supporting internal scientific management and coordination structures will be consolidated. The emphasis 
will be on setting up an infrastructure that promotes effective working through maximising resources, 
prioritising key tasks and increasing the quality and value of the work through well-targeted outputs.       
Transversal activities will be further supported via three Cross-unit projects (CUPs) launched by the Director 
in 2010. These time-limited, coordination vehicles provide a flexible forum for EMCDDA staff to come 
together on a technical issue that spans different aspects of the work programme. The Treatment CUP will 
ensure that the data sets remain coherent and supportive even though the methodological perspectives of 
the epidemiological and services monitoring of treatment provision differ. The Prison CUP will act as a 
catalyst for scaling up work in this important setting and a key activity will be the drafting of a prison 
monitoring strategy. The Modelling CUP will provide a forum for reviewing the utility and supporting the 
introduction of more complex and innovative analytical methods. 
Disseminating and valorising EMCDDA findings 
The EMCDDA’s communication strategy needs to remain pertinent and up to date if it is to be efficient and 
effective. In 2011, we will realign the strategy (last updated in 2007) with current needs, introducing relevant 
developments in the communication area. We will also refine our processes and key controls for output 
production. The marked increase in the EMCDDA’s publishing activities requires ongoing attention to this 
area if quality is to be maintained.  
We will develop our activities to evaluate and analyse the impact of EMCDDA communication actions (from 
both quantitative and qualitative perspectives). The development of an events management tool is a key 
element, as it will enable better monitoring and quantification of all EMCDDA activities that disseminate 
results and information. In 2010, we obtained feedback from the national focal points on the relevance of our 
products and on the activities they undertake to disseminate them. In 2011, we will work with them to 
improve national distribution channels and to facilitate the task of disseminating EMCDDA results. 
From March 2010 until end February 2011, the EMCDDA is chairing the Agencies’ Heads of Communication 
and Information Network (HCIN). Activities culminate with a week-long exhibition at the European Parliament 
at the end of January 2011 that is intended to raise awareness among MEPs of the role of the agencies 
within the EU institutional framework and the results they achieve. The HCIN network was set up in 2008 
with a mandate to increase the visibility of the EU agencies and strengthen communication and information 
about their activities/results. 
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II.1 Objectives and activities 
 
1. Core monitoring activities 
Specific objectives Main activities  
1.1. To produce a state-of-the-art 
annual review of developments in 
drug use and supporting statistics 
and methodological information 
o Perform all analysis, reviews and consultations necessary for the preparation of the Annual report package 
(including Statistical bulletin, Country overviews, country profiles and supporting web resources) 
o Conduct activities necessary to support and implement annual reporting cycles (in close coordination with Reitox 
focal points) 
• Production cycle 2011: data processing, cleaning and liaison with NFPs for data requests and all reporting 
tools 
• Production cycle 2012: preparation, revision (where necessary in consultation with Reitox NFPs) and launch of 
tools and processes for 2012 
o Review and analyse on an ongoing basis information relevant to understanding all facets of the European drug 
situation for producing the Annual report package 
o Monitor quality and timeliness of reports and provide appropriate feedback and support to data providers, and 
continue to develop quality assurance mechanisms 
o Launch a review of the structure and presentation of information in the Annual report  
1.2. To ensure efficient and 
methodologically sound data input, 
management, processing and 
preparation of data sets for analysis 
o Ensure full set of information collected by the EMCDDA is efficiently verified, managed and archived 
o Carry out routine management of Fonte and other data management tools 
o Undertake data processing, data preparation and provide support to statistical analysis to facilitate EMCDDA 
reporting 
1.3. To review the appropriateness 
of current data management and 
statistical processes. Introduce 
incrementally new practices where 
o Identify options for future development of data management and statistical systems and tools and processes by 
conducting a high-level review of data types collected and the appropriateness of the instruments used (qualitative, 
text-based, semi-structured, aggregated and disaggregated data) 
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Specific objectives Main activities  
they are required and assess future 
needs for processing different types 
of data 
o Continue to develop the Statistical bulletin and integrate interventions data (health and social responses tables and 
graphics) to improve its structure and completeness 
o Continue to develop and improve validation of data submitted to and extracted from Fonte 
o Investigate the possibility of receiving case-level data within the ‘data warehouse’ facility 
 
2. Key indicators and monitoring the epidemiology of the drug situation 
Specific objectives Main activities  
2.1. To strengthen the European 
expert network for each KI 
necessary for EMCDDA reporting 
o Promote implementation and development of each key indicator through maintaining a strong network and 
supporting the work of national experts and NFPs 
o Organise annual expert meetings and supporting activities, including ongoing review and development of 
methodological guidelines and tools 
o Continue to maintain and develop the key indicator gateway and provide access to implementation tools and 
supporting material  
o Engage, in partnership with NFPs and experts, in the review and analysis of data sets 
o Undertake analytical work necessary to meet reporting obligations and provide indicator data to support cross 
indicator and other analysis. 
2.2. To increase quality and 
comparability of key indicators 
o Assess the quality of information provided by NFPs and report back to them 
o Assess the level of implementation of each key indicator and report the progress made 
o Provide targeted support (through Reitox) to countries experiencing technical implementation difficulties 
2.3. To undertake developmental work necessary to ensure KI remain methodically sound and appropriate to EU data collection needs 
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Specific objectives Main activities  
A – General population surveys 
(GPS) 
o Collect and map detailed national GPS methodology (including questionnaires) 
o Encourage harmonisation of survey approaches and support opportunities for collaboration between different 
surveys in the EU 
o Follow up investigation of survey methods focusing on reliability and validity 
o Collaborate with ESPAD and HBSC including supporting the analysis of data; host the ESPAD annual conference 
o Improve the integration of youth survey data within EMCDDA reporting and provide support to youth survey 
networks  
B – Treatment demand indicator 
(TDI) 
o Finalise TDI revision process and elaborate the new protocol to be implemented in 2012 
o Liaise and build consensus with NFPs and national experts to support implementation of the new protocol 
o Investigate opportunities for disaggregated analysis 
o Improve TDI data collection (online template) 
C – Drug-related deaths indicator 
(DRD) 
o Improve tools for cohort data collection and analysis; prepare a protocol on mortality cohorts (EMCDDA Manual) 
o Support capacity development and common European analysis on mortality cohorts; liaise with national studies, 
experts and focal points (scientific paper) 
o Develop a better understanding of health issues associated with problem drug use and prepare report on ‘Mortality 
related to drug use: a comprehensive approach and public health implications’ (EMCDDA Selected issue) 
D – Problem drug use (PDU) and 
revised problem drug use indicator 
(PDU-R) 
o Analyse options for revision and update of PDU indicator (PDU-R) based on gaps and strengths in existing 
approaches  
o Review costs and benefits of innovative and established statistical options for estimation of PDU levels 
o Support national estimation efforts through technical assistance to NFPs on PDU estimations (2012)  
o Develop methods for interpolation of missing data in the PDU dataset  
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Specific objectives Main activities  
E – Drug-related infectious diseases 
indicator (DRID)  
o Update the DRID protocol module (toolkit) supported by consensus building exercise (EMCDDA Manual) 
o Review data and produce new analysis of HCV trends (scientific paper) 
o Ensure effective collaboration with EU bodies and international organisations, such as the EC, ECDC, WHO, 
UNAIDS and other relevant partners  
o Collaborate with other appropriate institutions (EC, ECDC) and EMCDDA EWS on alerts on bacterial infections 
and/or other infections related to drug use 
o Ensure continuation of DRID modelling network infrastructure by updating the central dataset and consolidating its 
infrastructure in order to examine risk factors (scientific paper) 
Developmental areas  
 
2.4. To better exploit data by in-
depth and cross-indicator analysis 
to address important 
policy/research questions 
o Refine measures to identify better and enable analysis of patterns of polydrug use (including alcohol and tobacco) 
in KI reporting formats and undertake ad-hoc analysis, including coordination of ESPAD study group (scientific 
paper)  
o Field test data collection of conditional prevalence in GPS surveys (polydrug use, including alcohol) 
o Analyse recent trends in heroin use and patterns (scientific paper) 
o Carry out analysis of clients entering treatment for use of stimulants including possible role of alcohol (scientific 
paper) 
2.5. To undertake methodological 
studies, reviews and analysis 
necessary to understand additional 
key aspects of EU drug situation  
o Explore issues of reliability and validity in lifestyle and attitudes measures in survey data 
o Perform a combined analysis of estimates of cannabis dependence (2011−12) (scientific paper; EMCDDA Manual 
in 2012) 
o Develop a prototype of harmonised TDI database (national level) (2011–12) 
o Pilot work on the harmonisation of datasets at national level including surveys (four additional countries) for 
mortality cohorts and TDI, and organise analysis workshop (data laboratories) based on these datasets with 
participating countries 
o Initiate developmental work to support European analysis of special mortality registries based on core national 
datasets including assessment of the role of alcohol together with drugs (scientific paper in 2012) 




3. Monitoring demand reduction responses, interventions and solutions applied to drug-related problems 
Specific objectives Main activities 
3.1. To exploit available data to provide a comprehensive 
report on EU demand reduction activities 
o Develop an integrated set of online health and social responses national overviews covering 
treatment responses and availability, and harm reduction responses 
o Provide technical support to the EC (DG SANCO) for preparing the second progress report 
for implementing the Council Recommendation on the prevention and reduction of health-
related harm associated with drug dependence of 18 June 2003 
o Prepare a report on heroin-assisted treatment in Europe (EMCDDA Insight) 
o Prepare a joint publication with ECDC that provides guidance on the prevention of infectious 
diseases among IDUs  
o Prepare a report on the cost of treatment (EMCDDA Selected issue) 
o Collate information on treatment of cannabis-related disorders 
o Collect qualitative information from research literature and service providers on drug users’ 
experience with reducing or stopping drug use (Thematic paper in the Voices series) 
3.2. To develop and explore potential new data sources 
on drug treatment and harm reduction 
o Investigate and, if appropriate, develop harmonised opiates substitution treatment (OST) 
database based on national OST clients databases 
o Investigate and develop models for collecting data from General Practitioners (GPs)  
o Investigate and develop models for collecting data from low-threshold agencies 
o Assess the feasibility of collecting data on costs of different treatment modalities 
3.3. To update and improve reporting on prevention 
activities  
o Draft and submit a Cochrane systematic review on media campaigns for the prevention of 
illicit substance use in young people (scientific paper) 
o Further improve and update online prevention profiles encompassing mass media 
campaigns, environmental strategies, universal prevention, selective prevention and 
indicated prevention 
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Specific objectives Main activities 
o Analyse trends in universal and selective prevention programmes in Europe (scientific paper) 
o Restructure the Best practice portal module on prevention with the help of the GRADE 
system  
o Continue to explore and conclude on new methods for cross-analysis of prevention trials (EU 
–US) (EMCDDA Thematic paper/Technical data sheet) 
o Prepare a European overview of the implementation of effective international prevention 
programmes (EMCDDA Thematic paper/Technical data sheet) 
 
Developmental areas 
3.4. To rationalise data collection approaches and tools for demand reduction into a coherent set of responses indicators 
General approach o Draw up an inventory of existing instruments for data collection 
o Develop a conceptual framework for a set of intervention indicators 
o Define a process for implementation 
A – in the area of social reintegration o Further conceptualise social reintegration within the health and social response area and 
identify social reintegration indicators in line with literature and TDI revision 
o Develop a social reintegration module for Best practice portal 
o Produce an EU overview on social exclusion and social reintegration (also integrated in the 
Country overviews) 
B – in the area of drug treatment o Develop an indicator/index on ‘access to treatment’ based on a literature review and 
consolidate datasets 
o Further develop an indicator/index on ‘provision of treatment’/treatment availability 
(methodological toolkit) 
o Pilot test the ‘Methodological toolkit for estimating number of clients in treatment’ 
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Specific objectives Main activities 
o Develop a concept for indicator/index ‘syringe availability’  
 
4. Transversal analysis 
Specific objectives Main activities 
4.1. To perform combined cross-indicator analysis for 
monitoring responses 
o Analyse, at national and EU level, treatment coverage (availability and accessibility of 
treatment) and in different sub groups of users 
o Develop a conceptual framework for analysing national and EU-level coverage and trends in 
harm reduction interventions 
o Continue exploring the interaction between alcohol-cannabis connection and its implications 
for responses 
o Explore drug- and alcohol-related problems in nightlife settings 
4.2. To perform cross-analysis between epidemiology 
and response indicators 
o Audit studies of drug use and responses among special populations (including prisons, high 
use/risk settings) 
o Prepare a study on understanding drug use in the context of models of dependency and 
compulsive behaviour (EMCDDA Insight)  
o Initiate work for a policy briefing on ethnic minorities (EMCDDA Drugs in focus) 
o Monitor ongoing developments in the measurement of prevalence of drug use among drivers 
and in driving accidents and responses 
o Initiate work for a report on drugs and tourism (EMCDDA Selected issue, 2012) 
o Initiate work for a report on addicted parents (EMCDDA Selected issue, 2012) 




Cross Unit Project (CUPs) 
4.3. To facilitate work in the treatment area to ensure that 
overall approach is coherent, supportive and scientifically 
sound 
o Draft a common strategy on data collection and analyses on treatment and consequently 
promote the harmonisation of database structures 
o Elaborate a conceptual framework for ‘drug treatment’ (explore the concept: treatment 
demand, need, provision, uptake, access, barriers, quality, policies and outcomes) 
o Create an internal forum for critically assessing the EMCDDA’s work in the treatment area 
and for sharing analytical insights 
o Propose a framework for improving scientific exchange on treatment monitoring in Europe 
and with partners from other regions 
4.4. To coordinate and scale up work related to 
monitoring the prison setting through evaluating the 
availability of prison-related information on drugs at the 
EMCDDA 
o Draft a monitoring strategy on drug use and responses in prison setting, including the 
development of indicators 
o Map and review data collection instruments on prisons (quantitative and qualitative) 
o Analyse input and draft report on prisons (EMCDDA Selected issue, 2012) and organise a 
Reitox academy on the topic 
o Continue collaboration on prison issues with EU and international organisations 
4.5. To provide a forum for identifying potential key 
policy-relevant analyses for future work at the EMCDDA 
including an assessment of their operational implications 
o Support new analyses and in-house peer exchange (scientific paper) 
o Review and evaluate new modelling approaches relevant to the EMCDDA’s work(publish 
results of review of new incidence estimation approach - scientific paper) 
o Explore the use of meta-analysis of studies to assess effectiveness of interventions 




5. Supply and supply reduction activities 
Specific objectives Main activities 
5.1. To collect, analyse and report on the data on drug-
related crime, supply and markets 
o Prepare a report on cannabis markets and developments (EMCDDA Insight)  
o Reconstruct historical data on drug-law offences (continuation) and on drug tablets in Europe 
o Prepare a paper on drug couriers in Europe (EMCDDA Technical data sheet/Thematic paper) 
o Prepare a methodology for describing the Europe’s specialised drug police units 
5.2. To further analyse and report on drug markets in 
Europe 
o Prepare a joint EMCDDA–Europol situation report on ecstasy (joint publication) 
o Conduct analysis necessary for a joint EMCDDA–Europol situation report on heroin (joint 
publication, 2012) 
o Draft a paper on ‘Modelling drug markets: cannabis retail trafficking’ (scientific paper) 
Developmental areas  
5.3. To support the definition, development and adoption 
of key indicators in the area of supply, drug-related crime, 
supply reduction and drug market indicators 
 
o Organise a second technical conference (following outcomes of the 2010 conference) on 
supply and supply reduction indicators 
o Strengthen the collaboration with external partners on drug supply and supply reduction 
(Europol and others) and seek consensus on measures and approaches required for the 
sustainable future collection of high-quality indicators  
o Create three expert working groups on drug markets, drug-related crime and drug supply 




EMCDDA work programme 2011 — Final (02/12/2010) 
 
20 
6. Monitoring new trends and developments and assessing the risks of new substances 
Specific objectives Main activities 
6.1. Implementation of the early warning mechanism 
6.1.1. To implement effectively the aspects of the Council 
decision on the information exchange, risk assessment 
and control of psychoactive substances (2005/387/JHA) 
that fall within the remit of the EMCDDA, such as the 
early warning system (EWS) and risk assessment 
exercise 
o Implement efficiently information exchange on new drugs (EWS) — timely notifications on 
new psychoactive substances, early warning substance profiles and regular updates of the 
European database on new drugs (EDND)  
o Maintain and further develop the Reitox EWS network; prepare a compendium of national 
EWS descriptions; provide rapid day-to-day feedback to national EWS; develop further the 
European database on new drugs (EDND)  
o Implement longer-term monitoring of new psychoactive substances (biannual EWS progress 
and final reports) 
o Assist the European Commission and the European Council with the assessment of Council 
Decision 2005/387/JHA; adapt rapidly the information exchange mechanism to the amended 
Council decision (if relevant) 
o If appropriate, prepare EMCDDA–Europol joint reports on a new psychoactive substance and 
undertake risk assessments; implement and operationalise further the new risk assessment 
guidelines (scientific article) 
o Prepare a publication on new groups of psychoactive substances in Europe (EMCDDA 
Monograph) (2) 
6.1.2. To integrate new information sources and enhance 
cooperation with forensic science networks 
o Implement structured Internet monitoring to assess the online availability of (new) 
psychoactive substances  
o Develop further links to forensic/toxicology laboratory networks 
o Compile a publication with the full set of drug profiles (booklet and poster) 
o Prepare two new online drug profiles (if appropriate) 
                                                     
(2) Due to rapid and substantial developments in the field of new psychoactive substances, it was decided that the EMCDDA Insight on new groups of psychoactive substances in Europe 
planned for 2010 will be extended and published as a Monograph.   
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Specific objectives Main activities 
6.6.3. To maintain transparency and accountability and to 
strengthen cooperation with key partners 
o Report to the European Parliament, the Council and the European Commission on the 
implementation of the Council decision (Annual report) 
o Cooperate closely with Europol, EMA, the European Commission and the EMCDDA 
Scientific Committee 
6.2. Emerging trends 
6.2.1. To further develop an integrated approach for data 
collection, monitoring and reporting on emerging drug 
trends 
o Start implementing an integrated approach for data collection, monitoring and information 
exchange on emerging drug trends 
o Produce a policy briefing on khat (EMCDDA Drugs in focus) 
o Produce a case study, topic to be defined (EMCDDA Thematic paper/Technical datasheet) 
6.2.2. To pilot new data sources and a trend-spotting 
network 
o Further develop a methodology to use the Internet as an indicator for emerging drug trends 
(linked with implementation of the Council decision) 
o Initial implementation of structured monitoring of misuse of medicines (in the context of illicit 
drug use) in Europe (linked with the Council decision and in close cooperation with EMA) 
o Establish a network of ‘trend spotters’ and organise a kick-off meeting 
o Explore the feasibility of developing a multidisciplinary project to assess and monitor illicit 
drugs in wastewater; organise a small expert meeting on this topic and prepare an EMCDDA 
conference for 2012 (if financing is available) 
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7. Improving Europe’s capacity to monitor and evaluate policies 
Specific objectives Main activities 
7.1. To increase analysis of national laws and legal basis 
for interventions and increase their visibility  
o Prepare a policy briefing on responding to new psychoactive substances (EMCDDA Drugs in 
focus) 
o Draft and release two new topic overviews (Prison penalties and Prison healthcare rules) 
o Conceptualise an index for legal responses 
o Promote use of ELDD database 
7.2. To examine specific drug policy models and better 
understand decision-making processes at the European, 
national and local levels 
o Prepare ‘National drug policy profiles’ (new EMCDDA series) 
o Review and develop frameworks for drug policy analysis 
o Conduct a study on drug policy advocacy groups in Europe (as part of a new series of drug 
policy actors in Europe) 
7.3. To develop quality standards, guidelines in the drug 
policy evaluation field 
o Prepare European guidelines for the evaluation of national drug strategies (EMCDDA 
Manual) 
o Develop an online section on the evaluation of national drug strategies and action plans 
7.4. To provide ongoing support to the EU drug policy 
review 
o Contribute to the evaluation of the EU drugs strategy and action plan 
o Provide appropriate support to the European Commission in this particular area 
7.5. To fine-tune the standard table on public expenditure 
to allow better understanding of costs related to 
implementation of drug policies  
o Carry out analysis of the public expenditure data collected and fine-tune the standard table 
on public expenditure 
7.6. To develop economic analysis on drug issues  o Conduct an empirical analysis which will model the impact of unemployment on drug issues 
(scientific paper) and contribute to a collection of papers on this topic (scientific papers) 
o Draft further chapters for the ‘Handbook of the economics of illicit drugs’ 
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8. Good practice, guidelines and quality standards, and cooperation with the scientific community 
Specific objectives Main activities 
8.1. To further develop and encourage exchange of 
information on evidence-based interventions 
o Continue to participate in an EU project on prevention standards and other partnership 
activities on standards and guidelines for interventions, harm reduction and social 
rehabilitation 
o Undertake joint action to carry out international comparison of prevention standards 
(UNODC, the Canadian Centre on Substance Abuse and others) 
o Define a strategy to expand and promote best practices in Europe 
o Conduct exploratory analysis of the impact of the Best practice portal 
8.2. To further develop the Best practice portal supporting 
evidence-based interventions 
o Prepare analysis of ‘History, methods and implementation of national treatment guidelines’ 
(EMCDDA Selected issue) 
o Draft a policy briefing on ‘Minimum quality standards of interventions’ (Drugs in focus) 
o Develop the Best practice portal treatment module integrating indicator-based datasets 
o Launch work for a report on ‘Therapeutic communities in Europe’ (Insights, 2012) 
8.3. To facilitate access to drug-related science and 
research and promote cooperation with the scientific 
community 
o Create an overview of drug-related research in the EU and Member States 
o Promote and facilitate EU drug-related research, such as ERA-Net, Marie Curie and other 
research activities, in particular under the 7th Framework Programme for Research and 
Technological Development,  and disseminate their results 
o Liaise regularly with the Commission to make use of existing EU funded research results in 
the field of illicit drugs and addiction related topics. 
o Support academic training programmes in the area of drugs and addiction 
o Continue to use the Scientific Committee to review and provide guidance on developments 
for the scientific audience 
o Draft a policy briefing on drug-related research (EMCDDA Drugs in focus) 
o Network with the scientific community and relevant organisations 
o Promote dissemination of EMCDDA scientific findings in the scientific community  
o Explore options for publishing in other scientific fora — journals, open source (cooperating 
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Specific objectives Main activities 
with ISAJE) 








Notes on timing 
Annual reporting  
Annual report on the state of the drugs problem in Europe 
 
1.1 First draft: end February  
Consultation with Member 
States: April 





Publication: November  
Selected issues 
• History, methods and implementation of national 
treatment guidelines (NFP contribution mandatory) 
• Cost of treatment (NFP contribution voluntary) 
• Mortality related to drug use: a comprehensive 









To be launched at 
appropriate intervals 
throughout the year taking 






Consultation with Member 
States: April 
Incorporation of comments: 
May 
Publication: mid July 
Country overviews (includes situation summary, data 
sheet and barometer) 
1.1 Production: January–May 
Publication: mid July 
National reports on the drug situation  1.1 Prepared by the NFPs 
Delivery to EMCDDA: 30 
October.  
Publication on EMCDDA 
website: mid July 
Support to the evaluation of the EU drugs strategy and action plan 
Situation and responses review since 2005 7.4  June 2011 
Outputs linked to the implementation of Council decision on new psychoactive substances 
(2005/387/JHA) 
EMCDDA–Europol annual report on the implementation of 
Council Decision (2005/387/JHA) on the information 
exchange, risk assessment and control of new 
psychoactive substances 
6.1.1 March 2011 
Risk assessment report on a new psychoactive substance 6.1.1 If requested 
Risk assessment report on Mephedrone  March 2011 
EMCDDA–Europol joint report on a new psychoactive 
substance 6.1.1 If appropriate 
Improved European database on new drugs (EDND)  6.1.2 Autumn 2011 
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Notes on timing 
Compendium of national EWS descriptions (booklet) 6.1.1 Autumn 2011 
Notifications of new psychoactive substances, early 
warnings; substance profiles  
6.1.1  Ongoing 
Drugs in focus policy briefings (titles indicative)  
Responding to psychoactive substances  7.1 March 2011 
Minimum quality standards of interventions 8.2 end 2011 
Drug-related research 8.3 April 2011 
Khat 6.2 2011 
Monographs 
  
New groups of psychoactive substances in Europe  6.1.1 2011 
Insights  
Cannabis market and production in Europe 5.1 2011 
Heroin-assisted treatment 3.1 July 2011 
Understanding drug use in the context of models of 
dependency and compulsive behaviour  
4.2 October 2011  
Manuals 
Drug-related infectious diseases (DRID) protocol module 
(toolkit) 
2.3.E 2011 
Mortality cohort protocol (linked to DRD) 2.3.C 2011 
European guidelines for the evaluation of national drug 
strategies 
7.3 2011 
National drug policy profiles 
(new series to be launched in 2011) 7.2 2011 
Joint publications  
The European ecstasy market (EMCDDA–Europol) 5.2 Autumn 2011 
Joint guidance on the prevention of infections among 
injecting drug users (ECDC−EMCDDA)  
3.1  June 2011 
Thematic papers and technical datasheets 
Emerging drug trends case study 6.2.1 2011 
Drug couriers in Europe 5.1 2011 
New methods for cross analysis of prevention trials (EU–
US) 
3.3 Early 2011 
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Notes on timing 
Overview of European implementation of effective 
international prevention programmes 
3.3 2011 
Drug users’ perspectives in quitting drug use (Voices) 2.5 Autumn 2011 
Estimation of prevalence of daily cannabis use in Europe 2.5 2011 
Assessing information availability on drug use and drug 
markets in Candidate and Potential Candidate Countries 
III.1.5  
Drug profiles 
Full set of drug profiles already published online (booklet 
and poster) 
6.1.2 Autumn 2011 
Two new online drug profiles (if appropriate and 
depending on needs) 
6.1.2 2011 
Online tools and web-based resources 
EMCDDA public website IV.1.3 Ongoing improvement of 
public website accessibility. 
Introduction of more 
theme/topic-based pages  
Best practice portal  
(including maintenance of EDDRA, EIB and PERK, 
publication of GRADE profilers in relevant sections, 
further work on prevention, preparation of social 
reintegration module) 
3.3, 3.4, 8.2 Ongoing update (treatment, 
prevention and harm 
reduction) and launch of 
new module (social 
reintegration) 
ELDD (European legal database on drugs) and legal topic 
overviews:  
Prison penalties  
Prison healthcare rules 
7.1 Ongoing update of website 
and legal topic overviews 
Country intervention profiles 1.1, 3.1, 3.4 October 2011 
General report of activities  
General report of activities including annual activity report 
of the EMCDDA’s authorising officer (for 2010) 
(EN)  
IV.3.6 March 2011 (with provisional 
accounts) 
May 2011 (with final 
accounts) 
Drugnet Europe 
Drugnet Europe newsletter (4 issues) IV.1.7 January, April, July, 
November 
 




Articles in scientific journals (indicative) Ref. to specific 
objective in work 
programme  
One of the EMCDDA’s priorities is to ensure that its findings feature regularly in scientific journals. The list below 
indicates articles that are expected to be published in 2011. However, please note that the review and revision 
process can be lengthy and not all submissions are likely to be accepted.  
Analysis of HCV trends 2.3.E 
Analysis of risk factors  2.3.E 
Polydrug use among 15- to 16-year-olds in Europe 2.4 
Clients entering treatment for use of stimulants (2011–12) 2.4 
Recent trends in heroin use and patterns 2.4 
Combined European mortality cohort analysis (2011–12) 2.5 
European overview of methods and estimations of cannabis dependence (2011–12) 2.5 
Universal and selective prevention trends in Europe, 2007 to 2010 3.3 
Media campaign interventions for the prevention of illicit drug use in young people 
(Cochrane review) 
3.3 
Heroin incidence 4.5 
Modelling drug markets: cannabis retail trafficking 5.3 
Modelling the impact of unemployment on drug treatment 7.6 
Impact of economic downturn on drug phenomena 7.6 
 
Participation in conferences and technical meetings 
Throughout the year, the EMCDDA gets called upon to present its work and findings and lecture at numerous 
conferences, technical meetings and university course. A comprehensive list of these contributions will be 
presented in the General report of activities 2011. 
 
External visits 
Throughout the year, the EMCDDA gets called upon to communicate findings and messages face-to-face — in 
the form of visits and briefings for policymakers and other interested groups. A comprehensive list of these 
external visits will be presented in the General report of activities 2011. 
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III. Supporting drug policy dialogue and technical cooperation 
1. International cooperation and collaboration with partners and technical assistance 
Specific objectives Main activities 
EU institutions, agencies and civil society 
III.1.1. To ensure effective collaboration with European 
institutions, agencies and civil society on drug-related 
issues  
o Support drug policy dialogue at EU level by providing expertise and technical information to 
the European Parliament, the Council and the European Commission  
o Collaborate with European agencies on cross-cutting drug-related issues (Europol, ECDC, 
EMA) and explore areas of possible future cooperation with other agencies (FRA, CEPOL, 
EFSA, Frontex) 
o Collaborate with civil society and transnational networks 
International partners 
III.1.2. To pursue technical cooperation with international 
partners on best practices in monitoring the drug situation 
o Exchange expertise, data and methodological information and tools with international 
partners such as: UNODC, WHO, Council of Europe Pompidou Group, CICAD, WCO, 
MAOC–N 
o Disseminate know-how on building regional drug information systems through the promotion 
of EMCDDA approaches and working methods, and using the joint Handbook on National 
Drug Observatories. 
o Support, as appropriate, the assessment of the UN declaration and plan of action 
o Ensure appropriate development of multinational and European health data collections 
projects (i.e. ECHI) 
o Contribute to various international conferences and expert meetings with EMCDDA expertise 
and experience  
European Neighbourhood Policy countries and other third countries 
III.1.3. To provide technical support to the European 
Neighbourhood Policy (ENP) countries for their potential 
o Prepare and keep updated a strategy document for the extension of the Reitox network to 
ENP countries 
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Specific objectives Main activities 
future participation in the work of the EMCDDA 
 
o Finalise and start implementing the technical proposal for ENP technical assistance project 
o Contribute to various international and European conferences with EMCDDA expertise and 
experience 
III.1.4. To coordinate, facilitate and support cooperation 
between the EMCDDA and other non-EU countries and 
organisations  
o Support the European Commission in relation to negotiations with non-EU countries 
regarding their future participation in the work of the EMCDDA in line with art. 21 of the 
EMCDDA recast regulation  
o Coordinate the negotiation, signing and implementation of the MoUs in line with art.20 of the 
EMCDDA recast regulation 
o Disseminate know-how on building national drug information systems through the promotion 
of the EMCDDA–CICAD joint manual (produced also in Arabic and Russian)  
o Update principles and methods for elaborating Country overviews of non-EU countries 
o Provide targeted support to EU-funded programmes if necessary resources are provided in 
line with the principles set out in the EMCDDA’s international strategy  
Technical assistance to candidate and potential candidate countries 
III.1.5. To prepare the candidate and potential countries 
to the EU for their participation in the EMCDDA 
 
o Implement IPA-3 technical assistance project 2010–11 
o Finalise accounting and reporting for the IPA3 project funded under the ENPI interregional 
programme and/or TAIEX instrument 
o Prepare for updated/new online country overviews, information maps and national reports 
produced within the framework of the IPA 3 project 
o Draw up a thematic publication on ‘Assessing information availability on drug use and drug 
markets in Candidate and Potential Candidate Countries’ 
o Disseminate know-how on building national drug information systems through the promotion 
of the EMCDDA–CICAD joint manual in Croatian and Turkish 
o Drafting, signing and implementing IPA-4 technical assistance project 2011-2012 
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IV. Supporting the achievement of results  
1. Communicating the EMCDDA’s findings to external audiences  
Specific objectives Main activities 
Up-to-date and pertinent communication strategy 
IV.1.1. To update the EMCDDA’s communication strategy o Realign the communication strategy (last updated in 2007) with current needs introducing 
relevant developments in the communication area 
o Delineate an action plan to implement the strategy 
Timeliness and quality of the EMCDDA products 
IV.1.2. To ensure publication of high-quality and timely 
products in line with targets committed to in the 2010–12 
work programme 
o Publish, launch and disseminate the outputs listed in the 2011 outputs list (see p. 24) 
o Complete the guidance documents and work processes used for the production of different 
outputs 
o Renew the Service Level Agreement with the Publications Office stipulating areas where 
improvements are needed 
o Put in place additional framework contract(s) to support production of outputs 
Getting the medium right 
IV.1.3. To develop online tools corresponding to audience 
needs and responsive to developments in technology 
 
o Continue to work on the reorganisation of the EMCDDA’s public website 
o Implement the outcome of the Content Management Application (CMA) road map project 
(executed in 2010) 
o Implement a web governance strategy 
o Complete the development and implementation of the events management tool; develop a 
more streamlined approach to publishing news across multiple platforms 
IV.1.4. To assure better quality and relevance of 
multilingual products 
o Continue to work with national focal points on the terminology/glossary project 
o Establish a more formalised approach with national focal points for collecting feedback on 
EMCDDA work programme 2011 — Final (02/12/2010) 
 
32 
Specific objectives Main activities 
translation quality and linguistic revision of multilingual products 
o Analyse current multilingual policy and publishing strategy (in context of update to 
communication strategy)  
Valorising outputs 
IV.1.5. To optimise dissemination activities o Review dissemination channels and assess their value and main target audience reached  
o Better quantify and monitor all EMCDDA activities that disseminate results and information 
(e.g. presentations, conferences, technical meetings, briefings with policymakers) as well as 
dissemination activities aimed at other multipliers (e.g. scientific journals)  
o Continue to analyse print-runs and introduce more flexible and less costly print-on-demand 
option offered by EU bookshop; reinforce EU bookshop as the general public’s gateway to 
EMCDDA publications 
o Improve national distribution channels through closer cooperation with NFPs and more 
flexible distribution approaches 
Responding better to differentiated needs 
IV.1.6. To ensure that different target groups are reached 
with the most suitable channel/product 
 
o Launch a survey to collect feedback from target user groups on relevance and importance of 
EMCDDA products 
o Devise a system to ensure improved coverage of relevant topics for policymakers 
o Find synergies through the work of the documentation team and scientific units for better 
reaching scientific audiences  
o Ensure better penetration of the practitioners’ group through work with scientific teams to 
identify key stakeholders 
o Continue to serve citizens through appropriate use of website and social media and by 
launching awareness-raising products on international days 
o Improve web statistics and metrics to better understand needs of online visitors 




Promoting active communication (media relations, events, briefings and conferences) 
IV.1.7. To enhance the EMCDDA’s reputation and 
recognition as the European central reference point and 
authoritative information source in the drugs field 
 
 
o Launch a three-phase project ‘Representing the EMCDDA’ and further develop tools and 
training activities that facilitate a coherent presentation of the EMCDDA’s purpose, values 
and identity (corporate identity and reputation management) 
o Launch a refresh of the EMCDDA Corporate identity and apply across products and 
premises 
o Promote excellence in public speaking, speech writing and presentation delivery by 
developing quality standards and supporting training activities 
o Continue to communicate the EMCDDA’s findings and messages face-to-face — in the form 
of visits and briefings for policymakers and other interested groups as well as making 
presentations at conferences  
o Ensure that the internal Rapid Response Team (RRT) mechanism is highly operational 
o Take a more proactive stance to being represented at events/exhibitions; organise presence 
at key annual events (Annual report launch, 26 June, promotional fairs, CND) and 
international conferences 
o Continue to: build sound contacts and relations with journalists (from general and specialist 
publications); provide media-friendly information with clearly defined messages; and assess 
impact of media coverage; and provide media training to EMCDDA staff 
Supporting scientific knowledge and research (library and documentation services) 
IV.1.8. To ensure access to information and recent 
scientific publications for EMCDDA staff through reliable 
and efficient information, library and documentation 
services 
o Provide and proactively disseminate information to support the research needs of the 
scientific staff, and other information needs within the EMCDDA 
o Evaluate, acquire and manage information resources and maintain facilities at the EMCDDA 
conducive to study and research  
o Assess the impact of the library and information services on EMCDDA research and output 




2. Governance, management and networks  
Specific objectives Main activities 
Internal organisation  
IV.2.1. To ensure efficient and effective functioning of the 
office by improving internal organisation and working 
processes  
 
o Evaluate the current work processes and management procedures and propose 
improvements  
o Revise internal coordination mechanisms 
IV.2.2. To coordinate scientific activities to ensure that 
resources are managed efficiently, that objectives are 
achieved and that quality control of outputs is assured 
o Develop new organisational structure by setting up internal scientific management group for 
the Scientific division and any necessary supporting processes 
o Launch internal top-level review of scientific work including methods, contents, data 
collection tools and procedures to ensure they are fit for purpose and adequate for 
anticipated future needs (preparatory work for the next three-year work programme)  
o Define the EMCDDA scientific strategy and ensure its effective implementation 
o Hold regular editorial group meetings with the Communication team to ensure tracking and 
quality control of outputs  
o Maintain and further develop internal quality control mechanisms and ensure efficient 
coordination across all EMCDDA units supporting implementation of scientific activities 
o Encourage and coordinate transversal activities and analysis, including monitoring and 
reviewing progress made by the CUPs on prison, treatment and modelling   
o Ensure that the scientific work of the agency reflects the current obligations set out in the 
Regulation and reflected in the three-year and annual work programme as well as the needs 
of the EU drug strategy and action plan 




Statutory bodies  
IV.2.3. To facilitate strategic decision-making processes 
and scientific advice by providing support to the 
EMCDDA statutory bodies  
o Coordinate, prepare and organise follow-up of the meetings and decisions of the 
Management Board, Executive Committee and Budget Committee  
o Assist and organise the work of the Scientific Committee  
Reitox network  
IV.2.4 To further develop the functioning, management 
and visibility of the Reitiox network  
o Implement the Reitox development strategy  
o Improve the working processes and further consolidate the grant management system  
o Ensure visibility of the EMCDDA and Reitox data collection activities  
o Organise two Reitox Academies one on prisons and another one on a selected topic 
according to the specific capacity development needs 
 
 
3. Administration and supporting core business  
Specific objectives Main activities 
Human resources  
IV.3.1. To maintain high quality of personnel 
administration 
o Administrate personnel rights, entitlements, obligations and benefits  
o Implement effective and efficient recruitment procedures  
o Provide training to EMCDDA staff according to the priorities so as to strengthen staff capacity 
and performance 
o Draw up the multiannual staff policy plan  
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Specific objectives Main activities 
IV.3.2. To further develop efficient HR policies, 
procedures and tools 
o Enhance planning and organisation of training actions based on identified needs 
o Implement the online recruitment tool 
o Assess the appraisal and promotion/reclassification processes 
o Draft and implement a new reclassification process for contract staff 
o Further develop the human resources database (HRDB) and make it accessible to staff 
members  
IV.3.3. To improve HR management and enhance 
scientific excellence and recognition of EMCDDA staff 
o Define and implement the EMCDDA HR strategy 
o Develop management competencies through training initiatives addressed at the EMCDDA’s 
managers 
Financial management 
IV.3.4. To ensure efficient and effective budget 
implementation  
o Make full use of the management and reporting functions of the ABAC system 
o Assess and evaluate procurement and contracting processes  
o Assess and analyse the internal control system  
o Improve processes for managing Reitox grant 
Accounting  
IV.3.5. To develop cost-based accounting o Design a model for cost-based accounting  
o Conduct a pilot test to apply the model designed and identify the best solution for its 
implementation 
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Planning and reporting  
IV.3.6. To administer effectively and develop planning, 
monitoring and reporting processes 
o Coordinate the preparation of the 2010 General report of activities  
o Ensure timely planning for the 2012 work programme  
o Carry out mid-year monitoring of the implementation of the 2011 and 2010−12 work 
programme  
o Manage the 2011 budget and prepare the 2012 preliminary draft budget and the relevant 
reporting tools 
o Develop activity-based management (ABM) and budget processes and tools for planning, 
management and reporting, along with cost-based accounting 
o Prepare for introducing performance indicators to assist in monitoring achievements  
Infrastructure and logistics  
IV.3.7. To improve work safety, sound environmental 
management and security in the buildings, including 
reducing utility costs and promoting use of renewable 
energy 
 
o Further develop warden system to ensure readiness and staff safety 
o Draw up service level agreements with concerned European Commission services for 
security-related issues 
o Promote use of renewable energy  
IV.3.8. To ensure suitable work environment and related 
services, and improve efficiency and effectiveness 
through promoting a customer-oriented approach 
 
o Ensure services of premises and their maintenance 
o Improve access to services through intranet-based tools 
o Improve health and safety at work  
ICT  
IV.3.9. To ensure planned upgrades and maintenance of 
data collection, data analysis and product dissemination 
instruments 
o Contribute to the implementation of the Data collection roadmap and the Data analysis 
programme by planning Fonte application development and contributing to the development 
of models for the future evolution of data architecture and supporting tools 
o Provide support and regular maintenance services, implementation of upgrades related to 
the annual cycle of drugs data collection, web content management operational services and 




o Contribute to the finalisation of a CMA roadmap and its implementation 
IV.3.10. To improve the reliability and quality of the 
services provided  
o Ensure the running status and the operational maintenance of all ICT services in production  
o Plan and implement actions for infrastructure replacement and development, and business 
continuity 
o Improve service definition, and implement a ‘Services catalogue’ 
IV.3.11. To increase efficiency in ICT resource utilisation  o Introduce and progressively implement a project evaluation matrix to track project planning 
and execution 
o Continue and improve use of established license and resource management 
o Establish incident, problem and configuration change procedures 
IV.3.12. To contribute to the introduction of best practices 
and standards of governance, planning and service 
management  
o Apply a Project and Project portfolio management approach for the planning, prioritising and 
follow up of projects and activities in their relation to the ICT work programme 
o Establish and implement an ICT resource utilisation strategy 
o Continue to introduce Information Technology Infrastructure Library (ITIL) recommendations 
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Abbreviations and acronyms 
BPP Best practice portal  HBSC  Health behaviour in school-
aged children 
CUP Cross-unit project  GRADE Grading of Recommendations 
Assessment, Development 
and Evaluation 
DRD Drug-related deaths  IDU Injecting drug use 
DRID Drug-related infectious 
diseases 
 KI  Key indicator 
EDDRA European drug demand 
reduction action 
 NFP National focal point 
EC European Commission  PDU Problem drug use 
EDND European database on new 
drugs 
 PDU-R Problem drug use revised 
EIB Evaluation instruments bank  PERK Prevention evaluation 
resources kit 
ELDD European legal database on 
drugs 
 RRT Rapid response team  
ESPAD European School Survey 
Project on Alcohol and Other 
Drugs  
 TDI Treatment demand indicator 
EWS Early warning system    
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Potential risk factors 
Risk factors 
Throughout 2010, and in the framework of a more systematic risk assessment exercise, the 
EMCDDA has identified potential risk factors that could affect its planned deliveries. The table 
below lists the main potential risks that could negatively impact on the expected outputs and 
compliance with objectives of the EMCDDA. A brief assessment of the likelihood of 
occurrence and of the potential impact of the risks identified is also provided.  
 Risk factors identified 
for delivery of the 
2010–12 work 
programme 
Likelihood of impact on the 2011 work 
programme 
1. Substantial change 




budget relying on 
the EC grant over 
the 2010–12 period 
The 2011 work programme has been drawn up 
on the basis of the EMCDDA’s draft budget for 
2011 which relies on EC funding of 
EUR 15 400 000. Any reduction in this sum could 









with a direct 
link to specific 










from EU institutions 
to provide technical 




An extensive number of core tasks in support of 
the EU institutions (contribution to the EU drugs 
strategy and action plan, implementation of the 
Council decision on new drugs, support to the 
second progress report for implementing the 
Council Recommendation of 18.6.2003, support 
to drug policy dialogue at the EU level by 
providing expertise and technical information to 
the European Parliament, the Council and the 
European Commission, amongst others) have 
been foreseen for 2011.  
However, additional requests from EU institutions 
to provide technical support for implementing 
actions and programmes would require priorities 
to be reviewed (1) and supplementary resources 
to be identified. Concerning, in particular, the 
implementation of the Council decision on new 
psychoactive substances, and in view of the high 
number of new substances (notably ‘legal highs’) 
appearing over a short time period, a significant 
risk exists that multiple risk assessment exercises 
will be required on these, which would pose an 
additional burden on the work programme and 










and third parties to 
provide expertise in 
specific domains 
The current level of requests can be 
accommodated in routine work, but a significant 
increase in demand for this type of expertise 
would need additional scientific resources 
dedicated to it and would need to be balanced 
against other priorities of the work programme (1). 
 4. Lack of proper 
funding for the 
NFPs in the 
Member States 
Decrease in the budgets allocated to the NFPs by 
the Member States may impact on the NFPs` 
capacity to fulfil their reporting obligations 




(leading to possible 
tsunamis) or floods 
 
The location of the EMCDDA new facilities, 
bordering the Tagus river, raises a potential risk 
of being affected by any of these natural 
catastrophes. 
The likely consequences of a major earthquake 
are hardly predictable and appropriate measures 
would have to be taken in order to deal with the 
resulting damages. The EMCDDA is presently 
located in an area of seismic activity. The 
likelihood of a tsunami comparable to the one that 
destroyed downtown Lisbon 255 years ago can 
be considered as very low, since it is clearly a 
rare phenomenon. A landslide of the building 
caused by earthquakes, although not very likely, 
cannot be ruled out.  
As regards Tagus flooding, some information 
available (notably a report issued by Unisys in 
2008) leads us to believe that the potential risk 
here is low. On the other hand, it is conceivable 
that a combination of heavy rain with Tagus high 
tides could cause flooding of the underground car 
park. Further mitigating measures to deal with 
this risk will have to be agreed with the 
Administration of the Port of Lisbon (APL), the 









might have an 
impact on the 
implementation 




6. Terrorist attacks The new facilities, as they are more visible than 
before, could, at least in theory, attract the 
attention of terrorist groups. The likelihood of 
such an event is considered as low, mostly 
because Portugal has no serious recent 
background of this kind of attack. Moreover, if the 
target of such actions were to be the EU 
institutions or the like, there are far more visible 
and emblematic institutions in Europe, a fact that 
should decrease the potential risk faced by the 
EMCDDA in this respect. 
                                                     
(1) The process for reviewing priorities is as follows: identify 
projects/meetings/studies/recruitments that can be delayed, downsized or cancelled and 
reassign resources appropriately.  












































Throughout 2010, certain specific risks have 
been identified and assessed in this sensitive 
area: 
Governance risks, notably linked to a) 
suboptimal investment decisions in IT; b) 
existence of certain weaknesses in the 
management of IT projects, notably due to a lack 
of a proper definition of IT needs; c) the 
deployment in production of IT developments 
and applications not fully tested; and d) belated 
or unsatisfactory responses from IT services in 
cases of emergencies, mainly due to a lack of 
properly documented procedures.  
Mitigating measures to deal with these risks have 
already been set in place, of which the most 
important have been a) setting up of a register 
with a categorisation of IT investments; b) 
participation of the EMCDDA in interinstitutional 
Framework Contracts which has ensured good 
quality and reliability of services at advantageous 
prices; c) a separation between development 
and production systems has been defined and 
enforced internally to some extent; and d) 
documentation of processes has been improved 
and led to a number of best practice examples in 
the agency. 
A wide range of additional measures and actions 
is expected to reduce the existing risks to 
tolerable levels no later than 2012 a) 
implementation of a portfolio management 
approach including listing of projects to be 
selected in view of the top priorities of the 
agency; b) further development of a ‘turn-key’ 
(rather than ‘man-days’) project approach; c) 
enforcement of a clearer separation between 
development and production systems in IT, while 
seeking a segregation of duties amongst staff 
operating in those environments; and d) better 
documentation of procedures, to be carried out 
under the projects I–Assets 2010 and  
I–DeskM2009.   
Technical risks, notably linked to a) software 
configuration management problems resulting 
from hasty installations of software, compounded 
by the absence of a properly developed 
configuration management system; b) lack of or 
inconsistent application of patching procedures, 
compounded by poor documentation of 
interventions and systems updates; and c) 
security violations, due to the lack of adequately 
documented procedures in the IT area.  
As a result of these weaknesses, negative effects 
on business continuity and recovery in case of 
events entailing loss of data and/or of operational 
capacity would most likely ensue, as they have 

























already materialised in the past.  
Although not yet fully sufficient in view of the 
agency’s needs, most relevant mitigating 
measures have already been implemented, such 
as a) setting up of an automatic monitoring 
system to deal with installed configurations, 
coupled with audits of configurations of specific 
systems; b) ‘ad hoc’ testing of potential 
consequences emerging from patching 
procedural weaknesses; c) contracting of 
assistance services in emergency cases where 
necessary. A business continuity plan (BCP) 
meant to deal also with these risks is presently 
under preparation.  
Furthermore, a comprehensive set of additional 
measures has been foreseen, it being expected 
that the existing risks in this field will be further 
reduced to nearly tolerable levels in 2011: a 
‘Definitive Software Library’ is expected to be set 
up before the end of 2010, a fully fledged BCP 
will be set up in the course of 2011, the 
implementation of the I–DeskM2009 project will 
address most of the software configuration 
management issues, a proper definition of 
patching specific procedures has been planned 
and the contracting of external audits, on areas 
deemed as particularly security sensitive, are 
amongst the most important initiatives for dealing 
with these risks.  
8. Unexpected 
departure of key 
members of staff 
 
Given the highly specialised and technical nature 
of much of the agency’s work, finding suitable 
replacements can be a time-consuming task. 
The EMCDDA 2010 reorganisation of scientific 
units provides sounder back-up arrangements for 
all staff concerned, whilst allowing a wider 
decentralisation of responsibilities in this key 
area. Investment in human resources ensures 
that arising needs can be acted upon with 
minimum delay in most cases. 
 





The worst case scenario would be linked to a major earthquake leading to a tsunami. As 
hinted above, an emergency/salvage plan conceived to address the resulting damages would 
be needed. Even so, disruption of the EMCDDA activities would probably ensue, the 
respective duration being dependent on the severity of the catastrophe and of the promptness 
of the aid received from public and/or private sources.  
It is to be noted that a very comprehensive insurance contract covering inter alia adverse 
effects arising from earthquakes, landslides, floods and terrorist attacks has been signed in 
2010 and would provide the necessary financial compensation in case such events 
materialise. The responsibility for further measures aimed at mitigating the risk of floods at the 
building belong to its owner, the APL, as stipulated under the leasing contract.  
Regarding specifically the IT area linked risks, the main consequences would be felt on 
business continuity and could also affect sound financial management, the latter to the extent 
that suboptimal investments in IT could occur, both in terms of purchases made and ‘value for 
money’ obtained thereby. To be noted, however, that the actions already taken coupled with 
those under implementation and planned are expected to bring these risks down to tolerable 
levels no later than 2012.  
Apart from the situations mentioned in the paragraphs above, the types of consequences that 
could arise from the listed risks would sequentially be:  
a)  reduced activities in support of partners and for non-core tasks; 
b) delay or postponement of necessary developmental work, support and capacity-
building activities; 
c) reduction in capacity for analytical work and transversal products; 
d) reduction in the scope or quality of planned outputs. 
Except for major catastrophes (notably tsunamis), should any of the above scenarios occur, a 
detailed assessment of their impact both in budgetary and operational terms would have to be 
conducted. The implications of this assessment would then need to be considered in terms of 
the overall priorities of the work programme.  
In case of major catastrophes, further measures would of course be needed. 
The EMCDDA will use and further strengthen its internal monitoring and evaluation capacity 
to prevent, manage and minimise the impact of the abovementioned risks. For this purpose, it 
has adopted a series of measures aimed at improving the planning, monitoring, assessment 
and execution of its work programme and budget, amongst which the recruitment of a staff 
member to deal with activity planning and monitoring is worth mentioning. 




Annex 2: Estimated allocation/use of the appropriations provided under the EMCDDA 2011 budget for the implementation of the EMCDDA 
2011 work programme (WP) 
 
The amounts indicated in the table below are based on the EMCDDA’s budget for 2011 that the EMCDDA’s Management Board should adopt in December 2010. This budget relies on the following revenues:  
• EUR 15.400.000 to be provided by the EC 2010 subsidy to the EMCDDA; 
• EUR 409.938 to be provided by Norway for its participation in the EMCDDA; 
• EUR 100.000 to be provided by Turkey’s for the first year of its participation in the EMCDDA 
 
Furthermore the EMCDDA’s 2011 budget enters as assigned appropriations a financing of EUR 400.000 from the IPA programme for the implementation of a project for technical assistance aimed at the «Preparation 
of IPA Beneficiaries for their participation in the EMCDDA » (IPA 3 project – 2nd year). 
The tables below present the estimated allocation of the EMCDDA’s 2011 budget appropriations for the implementation of the EMCDDA’s 2011 work programme: 
 
a) Vertical operations  
(Core business pursuant to the priority areas of activities defined in the EMCDDA founding regulation)  
Assigned human resources (fte/year)2 Allocated budget resources – Non assigned appropriations (€) 
Objectives and activities 
Main organisational 
actors for 
implementation O TA CA SNE Total HR 
For direct cost of 
operations3 
For indirect cost of 
operations4 Total budget  
1. Core monitoring activities Scientific director (SDI) 1,00 2,90     3,90 439.342 306.417 745.759 
2. Key indicators and monitoring the 
epidemiology of the drug situation EPI 0,70 6,20 3,90   10,80 1.086.263 848.539 1.934.802 
3. Monitoring responses, interventions 
and solutions applied to drug-related 
problems 
IBS 1,50 2,10 0,90   4,50 480.579 353.558 834.137 
4. Transversal analysis SDI + CUPs 0,30 1,80 0,20   2,30 222.617 180.707 403.324 
5. Supply and supply reduction SAT   2,50   1,00 3,50 351.163 274.990 626.153 
6. Monitoring new trends and 
developments and assessing the risks of 
new substances 
SAT   2,50 1,00   3,50 381.970 274.990 656.960 
7. Improving Europe’s capacity to 
monitor and evaluate policies POL   4,80 1,00   5,80 571.846 455.697 1.027.543 
8. Good practice, guidelines and quality 
standards, and cooperation with the 
scientific community 
IBS 0,50 3,20     3,70 399.907 290.703 690.610 
Total 4,00 26,00 7,00 1,00 38,00 3.933.687,00 2.985.601,00 6.919.288,00 
                                                     
2
 Fte/year = full time equivalent per year; O = officials; TA = temporary agents; CA = contract agents; SNE = seconded national experts 
3
 Appropriations for cost/expenditure for operational activities and staff directly involved in the implementation of the EMCDDA mission/task/WP 
4
 Overheads, i.e. appropriations for cost/expenditure for activities, equipment, infrastructure and staff that indirectly aim at implementing the EMCDDA mission/task/WP, as their immediate aim is to support operational 
activities and staff. These overheads are distributed to operational activities in proportion of the human resources assigned for the implementation of these activities. 





b) Transversal operations 
Assigned human resources (fte/year)1 Allocated budget resources – Non assigned appropriations (€) 
Objectives and activities Main organisational actors for implementation O TA CA SNE Total HR For direct cost of 
operations2 
For indirect cost of 
operations3 Total budget 
9. Communicating the EMCDDA’s 
findings to external audiences 
(including translation) 
COM 1,00 9,00 2,00   12,00 2.049.043 942.821 2.991.864 
Executive and Corporate 
Management (Dir+DIR office 
+Governing bodies’ activities) 
3,00 6,00 2,00   11,00 1.161.380 864.253 2.025.633 
10. Governance, management and 
networks 
RTX (network coordination 
+NFPs’ co-financed activities) 1,00 2,50 1,00   4,50 3.039.680 353.558 3.393.238 
11. International cooperation and 
collaboration with partners and 
technical assistance 
RTX (international cooperation) 
0,00 1,50 1,00   2,50 383.495 196.421 579.916 
Total 5,00 19,00 6,00  30,00 6.633.598,00 2.357.053,00 8.990.651,00 
GRAND TOTAL FOR OPERATIONS (a + b) 9,00 45,00 13,00 1,00 68,00 10.567.285,00 5.342.654,00 15.909.939,00 
 
c) Support to operations 
Assigned human resources (fte/year)1 
Objectives and activities Main organisational actors for implementation O TA CA SNE Total HR 
Allocated budget resources for direct cost of supporting 
activities to be distributed to operations3– Non assigned 
appropriations (€) 
12. Administration (infrastructure and 
resources/assets management)  ADM 3,00 13,00 7,00   23,00 3.815.275 
13. ICT support,(equipment and 
services) ICT 1,00 7,00 3,00   11,00 1.527.379 
Total 4,00 20,00 10,00  34,00 5.342.654,00 
__________________________ 
 
1 Fte/year = full time equivalent per year; O = officials; TA = temporary agents; CA = contract agents; SNE = seconded national experts 
2 Appropriations for cost/expenditure for operational activities and staff directly involved in the implementation of the EMCDDA mission/task/WP 
3 Overheads, i.e. appropriations for cost/expenditure for activities, equipment, infrastructure and staff that indirectly aim at implementing the EMCDDA mission/task/WP, as their immediate aim is to support operational 
activities and staff. These overheads are distributed to operational activities in proportion of the human resources assigned for the implementation of these activities. 
 





d) Special projects  
(Funded by supplementary appropriations from EU budget on top of the EU regular annual subsidy to the EMCDDA)  
 
Assigned human resources (fte/year)1 Allocated budget resources – Assigned appropriations (€) 
Objectives and activities 
Main organisational 
actors for 
implementation O TA CA SNE 
Total 
HR 
For direct cost of 
operations2 
For indirect cost of 
operations3 Total budget 
14. Preparation of IPA Beneficiaries Countries for 























1 Fte/year = full time equivalent per year; O = officials; TA = temporary agents; CA = contract agents; SNE = seconded national experts 
2 Appropriations for cost/expenditure for operational activities and staff directly involved in the implementation of the EMCDDA mission/task/WP 
3 Overheads, i.e. appropriations for cost/expenditure for activities, equipment, infrastructure and staff that indirectly aim at implementing the EMCDDA mission/task/WP, as their immediate aim is to support operational 
activities and staff. These overheads are distributed to operational activities in proportion of the human resources assigned for the implementation of these activities. 




Annex 3: List of the national focal points beneficiaries of the Reitox grant 
Beneficiaries for the Grant Agreement in 2011 
 
Please note that unless there is a reorganisation within the national public administration of the beneficiary countries, the 
beneficiaries of the grant are the same each year.  Based on the decision of the Management Board of the EMCDDA in 
December 2007 the maximum amount of the Grant receivable by the Focal Points is indexed annually by 2% in order to 
maintain the real value of the grant. As such the maximum amount of the Grant per country in 2011 will be 103.173 €. 
The potential beneficiaries for 2011 are: 
• Gesundheit Österreich GmbH, Stubenring 6 ; 1010 Wien ; Austria 
• Scientific Institute of Public Health - Patrimoine (IPH - Patrimoine), Rue Juliette Wytsman, n° 14 ; 1050 Brussels ; 
Belgium 
• National Centre for Addictions (NCA BG), Pirotska str. 117; 1303 Sofia, Bulgaria 
• ΕΘΝΙΚΟ ΚΕΝΤΡΟ ΤΕΚΜΗΡΙΩΣΗΣ ΚΑΙ ΠΛΗΡΟΦΟΡΗΣΗΣ ΓΙΑ ΤΑ ΝΑΡΚΩΤΙΚΑ (Cyprus National Monitoring 
Centre for Drugs and Drug Addiction - EKTEPN), Antidrugs Council, Magnolia Center - Offices 11-12; Strovolos 
Avenue n° 32; 2018 Nicosia, Cyprus 
• Úřad vlády České republiky (Office of the Government of the Czech Republic), Nabřeží Edvarda Beneše n° 4; 
118 01 Praha 1 - Malá Strana; Czech Republic 
• National Board of Health (Sundhedsstyrelsen), Islands Brygge, n° 67 ; 2300 Copenhagen S ; Denmark 
• Tervise Arengu Instituut (National Institute for Health Development - NIHD), Hiiu Street n° 42; 11619 Tallinn; 
Estonia 
• National Institute for Health and Welfare (THL), Mannerheimintie 166 ; 00271 Helsinki ; Finland 
• Observatoire Français des Drogues et des Toxicomanies (OFDT), Avenue du Stade de France 3 ; 93218 Saint 
Denis La Plaine Cedex ; France 
• Institut für Therapieforschung (IFT), Parzivalstrasse 25 ; 80804 Munich; Germany 
• University Mental Health Research Institute - Greek Reitox Focal Point (UMHRI), 2, Soranou tou Efesiou, 
Papagou; 115 27 Athens; Greece 
• Országos Epidemiológiai Központ (National Center for Epidemiology), Gyáli út n° 2-6; 1097 Budapest; Hungary 
• Health Research Board (HRB), Lower Baggot Street 73 ; Dublin 2 ; Éire / Ireland 
• Presidenza del Consiglio dei Ministri – Dipartimento Politiche Antidroga, Via della Vite 13 ; 00187 Roma ; Italy 
• Veselibas Ekonomikas Centrs - The Centre of Health Economics (CHE), Duntes Street No. 12/22 LV-1005 Riga; 
Latvia 
• Narkotikų Kontrol÷s Departamentas Prie Lietuvos Respublikos Vyriausyb÷s (Drug Control Department under the 
Government of the Republic of Lithuania - DCD), Šv. Stepono n° 27; 01139 Vilnius; Lithuania 
• Centre de Recherche Public - Santé (CRP-Santé), Rue Dicks 18 ; 1417 Luxembourg ; Grand Duchy of 
Luxembourg 
• Ministry for the Family and Social Solidarity (MFSS), Republic Street; Palazzo Ferreria; CMR02 Valletta; Malta 
• Stichting Trimbos-Instituut, Da Costakade, n° 45 ; 3521 VS Utrecht ; the Netherlands 
• Krajowe Biuro Do Spraw Przeciwdzialania Narkomanii (National Bureau for Drug Prevention - Polish National 
Focal Point), ul. Dereniowa n° 52-54; 02-776 Warsaw; Poland 
• Instituto da Droga e da Toxicodependência (IDT), Praça de Alvalade, n° 7 – 6º ; 1700 - 036 Lisboa ; Portugal 
• Inspectorate General Politiei Romane - IGRP, 13-15 Stefan Cel Mare Avenue, Bucharest ; Romania 
• Úrad vlády Slovenskej republiky (Office of the Government of the Slovak Republic), Námestie slobody n° 1; 813 
70 Bratislava; Slovak Republic 
• Inštitut za Varovanje Zdravja Republike Slovenije (Institute of Public Health of the Republic of Slovenia), 
Trubarjeva n° 2; 1000 Ljubljana; Slovenia 
• Government Delegation for the National Plan on Drugs, Calle Recoletos 22 ; 28001 Madrid; Spain 
• National Institute of Public Health - Statens Folkhälsoinstitut (FHI), SE 831 40 Östersund; Sweden 
• Department of Health - Sexual Health and Substance Misuse, Waterloo Road, Wellington House 133-155, 
London SE1 8UG, United Kingdom 




Annex 4: Template of the 2011 Reitox grant agreement 
 
GRANT AGREEMENT FOR AN ACTION 
AGREEMENT N° GA.11.RTX.###.1.0 
The European Union (“the Union”), represented by the European Monitoring Centre for Drugs and 
Drug Addiction (“the EMCDDA”), itself represented for the purposes of signature of this agreement by 
Alexis GOOSDEEL, Head of REITOX Coordination and International Cooperation Unit 
of the one part, 
and 
[full official name] 
[official legal form] 
[official registration no] 
[full official address] 
[VAT number], 
(“the beneficiary”), represented for the purposes of signature of this agreement by [name, 
forename and function] 
of the other part, 
hereafter referred to as “the parties to the agreement” 
Whereas Council Regulation (EEC) No 302/93 on the establishment of the European Monitoring 
Centre for Drugs and Drug Addiction provides, in Article 5, for the European Information Network on 
Drugs and Drug Addiction (REITOX), forming the infrastructure for collecting and exchanging 
information and documentation; 
Whereas REITOX National Focal Points have officially been designated in all Member States and are 
fully operational throughout the lifetime of the present grant agreement; 
Whereas the Management Board of the EMCDDA has unanimously decided on 3-5 July 2002, to 
establish a grant based system between the EMCDDA and the REITOX National Focal Points; 
Whereas the Management Board of the EMCDDA has adopted unanimously on 15-17 January 2003, 
the ‘Operating framework for the REITOX system’; 
Whereas the Management Board of the EMCDDA has adopted unanimously on 1-2 July 2009 the 
2010-2012 work programme of the EMCDDA; 




Whereas the Management Board of the EMCDDA has adopted unanimously on 9-10 December 
2010 (TBC), the structure and content of the work programme for 2011, and the corresponding 
division of credits for 2011; 
Whereas the Management Board of the EMCDDA has adopted unanimously on 9-10 December 
2010 (TBC), the 2011 budget and the carry over of credits from the 2010 financial year to the year 
2011. 
HAVE AGREED 
the Special Conditions and General Conditions below, and the following Annexes: 
Annex I Description of the action 
Annex II Estimated budget of the action 
Annex III Technical and financial implementation reports to be submitted 
Annex IV Guidelines for 2011 national reporting 
Annex V Interim Financial Reporting Template 
Annex VI Final Financial Reporting Template 
Annex VII Summary statement of expenses template 
Annex VIII Provisional schedule of 2011 EMCDDA meetings 
which form an integral part of this agreement (“ the agreement”). 
The terms set out in the Special Conditions shall take precedence over those in the other parts of the 
agreement. 
The terms of the General Conditions shall take precedence over those in the Annexes. 
 
I – SPECIAL CONDITIONS 
ARTICLE I.1 - PURPOSE 
I.1.1 The EMCDDA has decided to award a grant, under the terms and conditions set out in the 
Special Conditions, the General Conditions and the Annexes to the agreement, which the 
beneficiary hereby declares that he has taken note of and accepts, for the action entitled 
‘Active contribution by the National Focal Point to the implementation of the EMCDDA 
2011 work programme”(“the action”).  
I.1.2 The beneficiary accepts the grant and undertakes to do everything in his power to carry out 
the action as described in Annex I, acting on his own responsibility. This includes the 
participation in the meetings organized periodically by the EMCDDA, described in Annex VIII - 
Provisional schedule of 2011 EMCDDA meetings.   
 
ARTICLE I.2 – DURATION 
I.2.1 The agreement shall enter into force on the date when the last of the two parties signs. 




I.2.2 The action shall run from 1 January 2011 (“starting date of the action”; or from the date on 
which the beneficiary officially requested the grant) until 31 December 2011. 
 
ARTICLE I.3 – FINANCING THE ACTION 
I.3.1 The total cost of the action is estimated at EUR […], as shown in the estimated budget in 
Annex II. That budget shall give a detailed breakdown of the costs that are eligible for Unit  
funding under the terms of Article II.14, of any other costs that the action may entail, and of all 
receipts, so that receipts and costs balance. 
I.3.2 The total eligible costs of the action are estimated at EUR […], as shown in the estimated 
budget in Annex II. 
Indirect costs are eligible at a flat rate of 7% of the total direct costs eligible, subject to the 
conditions laid down in Article II.14.3. 
I.3.3 The EMCDDA shall contribute with 50% of the actual eligible costs approved by the 
EMCDDA, up to a maximum of 103.173 EUR (one hundred and three thousand, one 
hundred seventy three euro). The final amount of the grant shall be determined as specified 
in Article II.17, without prejudice to Article II.19. 
I.3.4 By way of exception to Article II.13, the beneficiary may, when carrying out the action, adjust 
the estimated budget by making transfers between the six headings of eligible costs, provided 
that this adjustment of expenditure does not affect the implementation of the action and 
transfer between the six headings does not exceed 10% of the amount of each heading of 
eligible costs for which the transfer is intended, and without exceeding the total eligible costs 
indicated in paragraph 2. ,. The beneficiary shall inform the EMCDDA accordingly in writing. 
I.3.5 By way of derogation from Article II.16.1, any conversion of actual costs into euro shall be 
made at the annual average of the monthly exchange rate published at the Official Journal of 
the European Union, or, failing that, at the annual average of the monthly accounting rate 
established by the Commission and published on its website. The year to be considered for 
the calculation of the above mentioned annual average, shall correspond to the duration of 
this agreement, as laid down in Article I.2.2 above.  
 
ARTICLE I.4 –PAYMENT ARRANGEMENTS 
I.4.1 Pre-financing: 
Within 45 days of the date when the signed agreement is returned by the beneficiary and 
upon receipt of the request for pre-financing, a payment representing a maximum of 40% of 
the total amount of the grant specified in Article I.3.3. shall be made to the beneficiary, 
providing that the balance payment for the previous year grant agreement with the EMCDDA 
was settled.  
 
 




I.4.2 Interim payment: 
Every request for interim payment shall be accompanied by the interim technical and financial 
implementation reports specified in Article II.15.3. The EMCDDA shall have 45 days to 
approve or reject the documents in question or to request additional supporting documents or 
information under the procedure laid down in Article II.15.3. In that case, the beneficiary shall 
have 45 days to submit the additional information or documents requested. 
The amount of the interim payment shall be determined on the basis of the eligible costs 
actually incurred, as shown in the interim statement and approved by the EMCDDA. In no 
circumstances may the interim payment exceed 80% of maximum amount of the grant 
specified in Article I.3.3. The amount of any pre-financing previously paid to the beneficiary 
shall be deducted. 
The interim payment shall be made to the beneficiary within 45 days following approval by the 
EMCDDA of the documents accompanying the request for interim payment. 
The EMCDDA may suspend the period for payment in accordance with the procedure in 
Article II.16.2.  
I.4.3 Payment of the balance 
The request for payment of the balance shall be accompanied by the final technical and 
financial implementation reports specified in Article II.15.4 and by an external audit report on 
the action’s accounts. The EMCDDA shall have 45 days to approve or reject the documents 
in question or to request additional supporting documents or information under the procedure 
laid down in Article II.15.4. In that case the beneficiary shall have 45 days to submit the 
additional information or new documents requested. 
A payment representing the balance of the grant determined in accordance with Article II.17 
shall be made to the beneficiary within 45 days following approval by the EMCDDA of the 
documents accompanying the request for payment of the balance. 
The EMCDDA may suspend the period for payment in accordance with the procedure in 
Article II.16.2.  
 
ARTICLE I.5 – SUBMISSION OF REPORTS AND OTHER DOCUMENTS 
The provisions relating to the production of the technical and financial implementation reports and 
other documents referred to in Article I.4 are contained in Annex III. 
 
ARTICLE I.6 – BANK ACCOUNT 
Payments shall be made to the beneficiary’s bank account or sub-account denominated in euro, as 
indicated in the financial identification form which was attached to the grant request. 
This account or sub-account shall allow the funds paid by the EMCDDA to be identified. 




The beneficiary shall inform the EMCDDA in writing each time the concerned bank account or sub-
account have changed, by sending a new signed and stamped financial identification form with the 
new bank account or sub-account details. 
If the funds paid to this account yield interest or equivalent benefits under the law of the State on 
whose territory the account is opened, such interest or benefits shall, if they are generated by 
pre-financing payments, be recovered by the EMCDDA as specified in Article II.16.4. 
 
ARTICLE I.7 –GENERAL ADMINISTRATIVE PROVISIONS 
I.7.1  Any communication - such as requests for payment, technical and financial information, 
reports and any other correspondence - in connection with the agreement shall be in writing, 
indicating the number of the agreement, and shall be sent to the following persons and 
addresses: 
For the beneficiary : 
Mr/Mrs ………………………………………………………………………………… 
Head of [country] Focal Point / Permanent NFP contact person 
[Official denomination] ………………………………………………………………. 
[Full official address] ………………………………………………………………… 
 
For the EMCDDA : 
 Mr. Frédéric DENECKER 
REITOX Network Manager 
European Monitoring Centre for Drugs and Drug Addiction 
Cais do Sodré 
PT - 1249-289 Lisbon 
Portugal 
I.7.2  In the event of modifications in the aforementioned persons and/or contact data, each 
concerned party commits itself to communicate in written to the other party the occurred 
modification within the best delay.  
In the above mentioned circumstances or in case of impediment of one of the above persons, 
each concerned party commits itself to ensure the continuity of the respective functions and 
namely, to communicate to the other party, the name and contacts of the person who will 
ensure the necessary replacement.   




ARTICLE I.8 – LAW APPLICABLE AND COMPETENT COURT 
The grant is governed by the terms of the agreement, the Union law applicable and, on a subsidiary 
basis, by the law of Portugal relating to grants. 
Any dispute between the parties arising from the interpretation or application of the provisions of the 
agreement, which cannot be settled amicably, shall be brought before the Court of First Instance of 
the European Union and, in the event of appeal, the Court of Justice of the European Union. 
 
ARTICLE I.9 – OWNERSHIP / USE OF RESULTS 
I.9.1 Ownership of the results of the action, including intellectual property rights, and of the reports 
and other documents related to it shall be vested, on an equal basis, in both the EMCDDA 
and the beneficiary. 
I.9.2 Both the EMCDDA and the beneficiary grant each other the right to make free use of the 
results of the action as they deem fit, provided they do not thereby breach their respective 
confidentiality obligations or existing intellectual property rights. 
 
ARTICLE I.10 – DATA PROTECTION 
All personal data contained in the agreement shall be processed in accordance with Regulation (EC) 
No 45/2001 of the European Parliament and of the Council on the protection of individuals with 
regard to the processing of personal data by the Community institutions and bodies and on the free 
movement of such data. Such data shall be processed solely in connection with the implementation 
and follow-up of the agreement by the EMCDDA, without prejudice to the possibility of passing the 
data to internal audit services, to the European Court of Auditors, to the Financial Irregularities Panel 
and/or to the European Anti-Fraud Office (OLAF) for the purposes of safeguarding the financial 
interests of the Union. 
Beneficiaries may, on written request, gain access to their personal data and correct any information 
that is inaccurate or incomplete. They should address any questions regarding the processing of their 
personal data to the EMCDDA. Beneficiaries may lodge a complaint against the processing of their 
personal data with the European Data Protection Supervisor at any time. 




II –GENERAL CONDITIONS 
PART A: LEGAL AND ADMINISTRATIVE PROVISIONS 
 
ARTICLE II.1 – LIABILITY 
II.1.1 The beneficiary shall have sole responsibility for complying with any legal obligations 
incumbent on him. 
II.1.2 The EMCDDA shall not, in any circumstances or on any grounds, be held liable in the event 
of a claim under the agreement relating to any damage caused during the action’s execution. 
Consequently, the EMCDDA will not entertain any request for indemnity or reimbursement 
accompanying any such claim. 
II.1.3 Except in cases of force majeure, the beneficiary shall make good any damage sustained by 
the EMCDDA as a result of the execution or faulty execution of the action. 
II.1.4 The beneficiary shall bear sole liability vis-à-vis third parties, including for damage of any kind 
sustained by them while the action is being carried out. 
 
ARTICLE II.2 – CONFLICT OF INTERESTS 
II.2.1 The beneficiary undertakes to take all the necessary measures to prevent any risk of conflicts 
of interests which could affect the impartial and objective performance of the agreement. Such 
conflict of interests could arise in particular as a result of economic interest, political or 
national affinity, family or emotional reasons, or any other shared interest. 
II.2.2. Any situation constituting or likely to lead to a conflict of interests during the performance of 
the agreement must be brought to the attention of the EMCDDA, in writing, without delay. The 
beneficiary shall undertake to take whatever steps are necessary to rectify this situation at 
once.  
II.2.3. The EMCDDA reserves the right to check that the measures taken are appropriate and may 
demand that the beneficiary take additional measures, if necessary, within a certain time. 
 
ARTICLE II.3 - OWNERSHIP/USE OF THE RESULTS 
II.3.1 Unless stipulated otherwise in the agreement, ownership of the results of the action, including 
industrial and intellectual property rights, and of the reports and other documents relating to it 
shall be vested in the beneficiary. 
II.3.2 Notwithstanding paragraph 1, the beneficiary grants the EMCDDA the right to make free use 
of the results of the action as it deems fit, provided it does not thereby breach its 
confidentiality obligations or existing industrial and intellectual property rights. 
 





ARTICLE II.4 – CONFIDENTIALITY 
The EMCDDA and the beneficiary undertake to preserve the confidentiality of any document, 
information or other material directly related to the subject of the agreement that is duly classed as 
confidential, if disclosure could cause prejudice to the other party. The parties shall remain bound by 
this obligation beyond the closing date of the action. 
 
ARTICLE II.5 – PUBLICITY 
II.5.1 Unless the EMCDDA requests otherwise, any communication or publication by the beneficiary 
about the action, including at a conference or seminar, shall indicate that the action has 
received funding from the Union. 
Any communication or publication by the beneficiary, in any form and medium, shall indicate 
that sole responsibility lies with the author and that the EMCDDA is not responsible for any 
use that may be made of the information contained therein. 
II.5.2 The beneficiary authorises the EMCDDA to publish the following information in any form and 
medium, including via the Internet: 
- the beneficiary’s name and the address, 
- the subject and purpose of the grant, 
- the amount granted and the proportion of the action’s total cost covered by the funding. 
Upon a reasoned and duly substantiated request by the beneficiary, the EMCDDA may agree 
to forgo such publicity if disclosure of the information indicated above would risk 
compromising the beneficiary’s security or prejudicing his commercial interests. 
 
ARTICLE II.6 – EVALUATION 
Whenever the EMCDDA carries out an interim or final evaluation of the action’s impact measured 
against the objectives of the EMCDDA work programme concerned, the beneficiary undertakes to 
make available to the EMCDDA and/or persons authorised by it all documents or information liable, 
by their nature, to permit the evaluation to be successfully completed and to give them the rights of 
access specified in Article II.19. 
 
ARTICLE II.7 – SUSPENSION 
II.7.1 The beneficiary may suspend implementation of the action if exceptional circumstances make 
this impossible or excessively difficult, notably in the event of force majeure. He shall inform 
the EMCDDA without delay, giving all the necessary reasons and details and the foreseeable 
date of resumption. 




II.7.2 If the EMCDDA does not terminate the agreement under Article II.11.2, the beneficiary shall 
resume implementation once circumstances allow and shall inform the EMCDDA accordingly. 
The duration of the action shall be extended by a period equivalent to the length of the 
suspension. In accordance with Article II.13, a supplementary written agreement shall be 
concluded to extend the duration of the action and to make any amendments that may be 
necessary to adapt the action to the new implementing conditions. 
 
ARTICLE II.8 – FORCE MAJEURE 
II.8.1 Force majeure shall mean any unforeseeable exceptional situation or event beyond the 
parties’ control which prevents either of them from performing any of their obligations under 
this agreement, was not attributable to error or negligence on their part, and proves 
insurmountable in spite of all due diligence. Defects in equipment or material or delays in 
making them available (unless due to force majeure) , labour disputes, strikes or financial 
difficulties cannot be invoked as force majeure by the defaulting party.  
II.8.2 If either party is faced with force majeure, it shall notify the other party without delay by 
registered letter with acknowledgement of receipt or equivalent, stating the nature, probable 
duration and foreseeable effects. 
II.8.3 Neither of the parties shall be held in breach of their obligations under the agreement if they 
are prevented from fulfilling them by force majeure. The parties shall make every effort to 
minimize damage to a minimum.  
II.8.4. The action may be suspended in accordance with Article II.7. 
 
ARTICLE II.9 – AWARD OF CONTRACTS 
II.9.1 If the beneficiary has to conclude contracts in order to carry out the action and the 
corresponding costs are included in one of the headings of eligible costs according to the 
estimated budget, he shall award the contract to the bid offering best value for money; in 
doing so he shall take care to avoid any conflict of interests.  
II.9.2 Contracts as referred to in paragraph 1 may be awarded only in the following cases: 
(a) they may only cover the execution of a limited part of the action; 
(b) recourse to the award of contracts must be justified having regard to the nature of the 
action and what is necessary for its implementation; 
(c) the tasks concerned must be set out in Annex I and the corresponding estimated costs 
must be set out in detail in the budget estimation in Annex II. 
(d) any recourse to the award of contracts while the action is under way, if not provided for in 
the initial grant application, shall be subject to prior written authorisation by the EMCDDA. 
(e) the beneficiary shall retain sole responsibility for carrying out the action and for 
compliance with the provisions of the agreement. The beneficiary must undertake to make the 




necessary arrangements to ensure that the contractor waives all rights in respect of the 
EMCDDA under the agreement. 
(f) the beneficiary must undertake to ensure that the conditions applicable to him under 
Articles II.1, II.2, II.3, II.4, II.5, II.6, II.10 and II.19 of the agreement are also applicable to the 
contractor. 
 
ARTICLE II.10 – ASSIGNMENT 
II.10.1 Claims against the EMCDDA may not be transferred.  
II.10.2. In exceptional circumstances, where the situation warrants it, the EMCDDA may authorise the 
assignment to a third party of the agreement and payments flowing from it, following a written 
request to that effect, giving reasons, from the beneficiary. If the EMCDDA agrees, it must 
make its agreement known in writing before the proposed assignment takes place. In the 
absence of the above authorisation, or in the event of failure to observe the terms thereof, the 
assignment shall not be enforceable against and shall have no effect on the EMCDDA. 
II.10.3. In no circumstances shall such an assignment release the beneficiary from his obligations to 
the EMCDDA. 
 
ARTICLE II.11 – TERMINATION 
II.11.1 Termination by the beneficiary 
In duly justified cases, the beneficiary may withdraw his request for a grant and terminate the 
agreement at any time by giving 60 days’ written notice stating the reasons, without being required to 
furnish any indemnity on this account. If no reasons are given or if the reasons given are rejected by 
the EMCDDA, the beneficiary shall be deemed to have terminated this agreement improperly, with 
the consequences set out in the third subparagraph of paragraph 4 of this article. 
II.11.2 Termination by the EMCDDA 
The EMCDDA may terminate the agreement, without any indemnity on its part, in the 
following circumstances: 
(a) in the event of a change to the beneficiary’s legal, financial, technical,  organisational or 
ownership situation that is liable to affect the agreement substantially or to call into 
question the decision to award the grant; 
(b) if the beneficiary fails to fulfil a substantial obligation incumbent on him under the terms of 
the agreement, including its annexes; 
(c) in the event of force majeure, notified in accordance with Article II.8, or if the action has 
been suspended as a result of exceptional circumstances, notified in accordance with 
Article II.17; 




(d) if the beneficiary is declared bankrupt, being wound up is having his affairs administered 
by the courts, has entered into arrangements with creditors, has suspended business 
activities, is the subject of any other similar proceedings concerning those matters, or is in 
an analogous situation arising from a similar procedure provided for in national legislation 
or regulations;  
(e) where the EMCDDA has evidence or seriously suspects the beneficiary or any related 
entity or person, of professional misconduct; 
(f)  if the beneficiary has not fulfilled obligations relating to the payment of social security 
contributions or the payment of taxes in accordance with the legal provisions of the 
country in which it is established; 
(g)  where the EMCDDA has evidence or seriously suspects the beneficiary or any related 
entity or person, of fraud, corruption, involvement in a criminal organisation or any other 
illegal activity detrimental to the Unit’s financial interests; 
(h) where the EMCDDA has evidence or seriously suspects the beneficiary or any related 
entity or person, of substantial errors, irregularities or fraud in the award procedure or the 
performance of the grant; 
(i)  if the beneficiary has made false declarations or submits reports inconsistent with reality to 
obtain the grant provided for in the agreement. 
In the cases referred to in points (e), (g) and (h) above, any related person shall mean any 
physical person with powers of representation, decision-making or control in relation to the 
beneficiary. Any related entity shall mean in particular any entity which meets the criteria laid 
down by Article 1 of the Seventh Council Directive n° 83/349/EEC of 13 June 1983. 
II.11.3 Termination procedure 
The termination procedure is initiated by registered letter with advice of delivery or equivalent. 
In the cases referred to in points (a), (b) (d), (e), (g) and (h) above, the beneficiary shall have 
30 days to submit his observations and take any measures necessary to ensure continued 
fulfilment of his obligations under the agreement.  If the EMCDDA fails to confirm acceptance 
of these observations by giving written approval within 30 days of receiving them, the 
termination procedure shall continue to run. 
Where notice is given, termination shall take effect at the end of the period of notice, which 
shall start to run from the date when notification of the EMCDDA’s decision to terminate the 
agreement is received.  
If notice is not given in the cases referred to in points (c), (f) and (i) above termination shall 
take effect from the day following the date on which notification of the EMCDDA’s decision to 
terminate the agreement is received. 
II.11.4 Effects of termination 
In the event of termination, payments by the EMCDDA shall be limited to the eligible costs 
actually incurred by the beneficiary up to the date when termination takes effect, in 




accordance with Article II.17. Costs relating to current commitments that are not due to be 
executed until after termination shall not be taken into account. 
The beneficiary shall have 60 days from the date when termination takes effect, as notified by 
the EMCDDA, to produce a request for final payment in accordance with Article II.15.4. If no 
request for final payment is received within this time limit, the EMCDDA shall not reimburse 
the expenditure incurred by the beneficiary up to the date of termination, and it shall recover 
any amount if its use is not substantiated by the technical implementation reports and 
financial statements approved by the EMCDDA. 
By way of exception, at the end of the period of notice referred to in paragraph 3, where the 
EMCDDA is terminating the agreement on the grounds that the beneficiary has failed to 
produce the final technical implementation report and financial statement within the deadline 
stipulated in Article I.5 and the beneficiary has still not complied with this obligation within two 
months following the written reminder sent by the EMCDDA by registered letter with advice of 
delivery or equivalent, the EMCDDA shall not reimburse the expenditure incurred by the 
beneficiary up to the date on which the action ended and it shall recover any amount if its use 
is not substantiated by the technical implementation reports and financial statements 
approved by the EMCDDA. 
By way of exception, in the event of improper termination by the beneficiary or termination by 
the EMCDDA on the grounds set out in points (e), (f) or (g) of paragraph 2, the EMCDDA may 
require the partial or total repayment of sums already paid under the agreement on the basis 
of technical implementation reports and financial statements approved by the EMCDDA, in 
proportion to the gravity of the failings in question and after allowing the beneficiary to submit 
his observations. 
 
ARTICLE II.12 – REGULATORY FINANCIAL PENALTIES 
By virtue of the Financial Regulation applicable to the general budget of the European Communities, 
any beneficiary declared to be in grave breach of his obligations shall be liable to financial penalties 
of between 2% and 10% of the value of the grant in question, with due regard for the principle of 
proportionality. This rate may be increased to between 4% and 20% in the event of a repeated 
breach in the five years following the first. The beneficiary shall be notified in writing of any decision 
by the EMCDDA to apply such financial penalties. 
 
ARTICLE II.13 - AMENDMENTS 
II.13.1 Any amendment to the agreement must be the subject of a written supplementary agreement 
concluded between the parties. No oral agreement may bind the parties to this effect. 
II.13.2 The supplementary agreement may not have the purpose or effect of making changes to the 
agreement which might call into question the decision awarding the grant or result in unequal 
treatment of applicants. 
II.13.3 If the request for amendment is made by the beneficiary, he must send it to the EMCDDA in 
good time before it is due to take effect and at all events two months before the closing date 
of the action, except in cases duly substantiated by the beneficiary and accepted by the 
EMCDDA.




PART B - FINANCIAL PROVISIONS 
ARTICLE II.14 – ELIGIBLE COSTS 
II.14.1 Eligible costs of the action are costs actually incurred by the beneficiary, which meet the 
following criteria: 
– they are incurred during the duration of the action as specified in Article I.2.2 of the 
agreement, with the exception of costs relating to final reports and certificates on the 
action’s financial statements and underlying accounts; 
– they are connected with the subject of the agreement and they are indicated in the 
estimated overall budget of the action; 
– they are necessary for the implementation of the action which is the subject of the grant; 
– they are identifiable and verifiable, in particular being recorded in the accounting records 
of the beneficiary and determined according to the applicable accounting standards of the 
country where the beneficiary is established and according to the usual cost-accounting 
practices of the beneficiary; 
– they comply with the requirements of applicable tax and social legislation; 
– they are reasonable, justified, and comply with the requirements of sound financial 
management, in particular regarding economy and efficiency. 
The beneficiary’s internal accounting and auditing procedures must permit direct 
reconciliation of the costs and revenue declared in respect of the action with the 
corresponding accounting statements and supporting documents. 
II.14.2 The eligible direct costs for the action are those costs which, with due regard for the 
conditions of eligibility set out in Article II.14.1, are identifiable as specific costs directly 
linked to performance of the action and which can therefore be booked to it direct. In 
particular, the following direct costs are eligible provided that they satisfy the criteria set out 
in the previous paragraph: 
- the cost of staff assigned to the action, comprising actual salaries plus social security 
charges and other statutory costs included in the remuneration, provided that this does not 
exceed the average rates corresponding to the beneficiary's usual policy on remuneration. 
The corresponding salary costs of personnel of national administrations are eligible to the 
extent that they relate to the cost of activities which the relevant public authority would not 
carry out if the project concerned were not undertaken; 
- travel and subsistence allowances for staff taking part in the action, provided that they are in 
line with the beneficiary's usual practices on travel costs or do not exceed the scales 
approved annually by the EMCDDA; 
- the purchase cost of equipment (new or second-hand), provided that it is written off in 
accordance with the tax and accounting rules applicable to the beneficiary and generally 
accepted for items of the same kind. Only the portion of the equipment's depreciation 
corresponding to the duration of the action and the rate of actual use for the purposes of the 
action may be taken into account by the EMCDDA, except where the nature and/or the 
context of its use justifies different treatment by the EMCDDA; 




- costs of consumables and supplies, provided that they are identifiable and assigned to the 
action; 
- costs entailed by other contracts awarded by the beneficiary for the purposes of carrying out 
the action, provided that the conditions laid down in Article II.9 are met; 
- costs arising directly from requirements imposed by the agreement (dissemination of 
information, specific evaluation of the action, audits, translations, reproduction, etc.), 
including the costs of any financial services (especially the cost of financial guarantees); 
II.14.3 The eligible indirect costs for the action are those costs which, with due regard for the 
conditions of eligibility described in Article II.14.1, are not identifiable as specific costs directly 
linked to performance of the action which can be booked to it direct, but which can be 
identified and justified by the beneficiary using his accounting system as having been incurred 
in connection with the eligible direct costs for the action. They may not include any eligible 
direct costs. 
By way of derogation from Article II.14.1, the indirect costs incurred in carrying out the action 
may be eligible for flat-rate funding fixed at not more than 7% of the total eligible direct costs. 
If provision is made in Article I.3.2 for flat-rate funding in respect of indirect costs, they need 
not be supported by accounting documents.  
II.14.4 The following costs shall not be considered eligible: 
- return on capital; 
- debt and debt service charges; 
- provisions for losses or potential future liabilities; 
- interest owed; 
- doubtful debts; 
- exchange losses; 
- VAT, unless the beneficiary can show that he is unable to recover it according to the 
applicable national legislation; 
- costs declared by the beneficiary and covered by another action or work programme 
receiving a Union grant; 
- excessive or reckless expenditure. 
II.14.5 Contributions in kind shall not constitute eligible costs. However, the EMCDDA can accept, if 
considered necessary and appropriate, that the co-financing of the action referred to in Article 
I.3.3 should be made up entirely or in part of contributions in kind. In this case, the value 
calculated for such contributions must not exceed: 
- the costs actually borne and duly supported by accounting documents of the third parties 
who made these contributions to the beneficiary free of charge but bear the corresponding 
costs; 




- the costs generally accepted on the market in question for the type of contribution 
concerned when no costs are borne. 
Contributions involving buildings shall not be covered by this possibility. 
In the case of co-financing in kind, a financial value shall be placed on the contributions and 
the same amount will be included in the costs of the action as ineligible costs and in receipts 
from the action as co-financing in kind. The beneficiary shall undertake to obtain these 
contributions as provided for in the agreement. 
II.14.6 By way of derogation from paragraph 3, indirect costs shall not be eligible under a project 
grant awarded to a beneficiary who already receives an operating grant from the EMCDDA 
during the period in question. 
ARTICLE II.15 – REQUESTS FOR PAYMENT 
Payments shall be made in accordance with Article I.4 of the Special Conditions. 
II.15.1 Pre-financing 
Pre-financing is intended to provide the beneficiary with a float 
Where required by the provisions of Article I.4 on pre-financing, the beneficiary shall furnish a 
financial guarantee from a bank or an approved financial institution established in one of the Member 
States of the Union. The guarantor shall stand as first call guarantor and shall not require the 
EMCDDA to have recourse against the principal debtor (the beneficiary). 
The financial guarantee shall remain in force until final payments by the EMCDDA match the 
proportion of the total grant accounted for by pre-financing. The EMCDDA undertakes to release the 
guarantee within 30 days following that date.  
II.15.2 Further pre-financing payments 
Where pre-financing is divided into several instalments, the beneficiary may request a further pre-
financing payment once he has used up the percentage of the previous payment specified in the 
provisions of Article I.4 on further pre-financing. The request shall be accompanied by the following 
documents: 
- a detailed statement of the eligible costs actually incurred; 
- where required by the above-mentioned provisions of Article I.4, a financial guarantee in 
accordance with paragraph 1 of this article; 
- where required by the above-mentioned provisions of Article I.4, a certificate on the action's 
financial statements and underlying accounts, produced by an approved auditor or in case of 
public bodies, by a competent and independent public officer; 
- any other documents in support of his request that may be required in support of the request for 
further pre-financing payments. 
The documents accompanying the request for payment shall be drawn up in accordance with the 
relevant provisions in Article I.5 and the annexes. 




II.15.3 Interim payment 
Interim payments are intended to reimburse the beneficiary for expenditure on the basis of a detailed 
statement of the costs incurred, once the action has reached a certain level of completion. It may 
clear all or part of any pre-financing. 
By the appropriate deadline indicated in Article I.5, the beneficiary shall submit a request for interim 
payment accompanied by the following documents: 
- an interim report on implementation of the action; 
- an interim financial statement of the eligible costs actually incurred, following the structure of the 
estimated budget; 
- where required by the provisions of Article I.4 on interim payment, a certificate on the action's 
financial statements and underlying accounts, produced by an approved auditor or in case of 
public bodies, by a competent and independent public officer. The certificate shall certify, in 
accordance with a methodology approved by the EMCDDA, that the costs declared by the 
beneficiary in the financial statements on which the request of payment is based are real, 
accurately recorded and eligible and that all receipts have been declared, in accordance with the 
agreement. 
The documents accompanying the request for payment shall be drawn up in accordance with the 
relevant provisions in Article I.5 and the annexes. The beneficiary shall certify that the information 
provided in his request for payment is full, reliable and true. He shall also certify that the costs 
incurred can be considered eligible in accordance with the agreement, that all receipts have been 
declared, and that his request for payment is substantiated by adequate supporting documents that 
can be checked. 
On receipt of these documents, the EMCDDA shall have the period specified in Article I.4 in order to: 
- approve the interim report on implementation of the action; 
- ask the beneficiary for supporting documents or any additional information it deems necessary to 
allow the approval of the report; 
- reject the report and ask for the submission of a new report. 
Failing a written reply from the EMCDDA within the time limit for scrutiny indicated above, the report 
shall be deemed to have been approved. Approval of the report accompanying the request for 
payment shall not imply recognition of their regularity or of the authenticity, completeness and 
correctness of the declarations and information they contain. 
If additional information or a new report is requested, the time limit for scrutiny shall be extended by 
the time it takes to obtain this information. The beneficiary shall be informed of that request and the 
extension of the delay for scrutiny by means of a formal document. The beneficiary shall have the 
period laid down in Article I.4 to submit the information or new documents requested. 
Extension of the delay for approval of the report may delay the payment by the equivalent time.  
Where a report is rejected and a new report requested, the approval procedure described in this 
article shall apply. 




In the event of renewed rejection, the EMCDDA reserves the right to terminate the agreement by 
invoking Article II.11.2(b). 
II.15.4 Payment of the balance 
Payment of the balance, which may not be repeated, is made after the end of the action on the basis 
of the costs actually incurred by the beneficiary in carrying out the action. It may take the form of a 
recovery order where the total amount of earlier payments is greater than the amount of the final 
grant determined in accordance with Article II.17. 
By the appropriate deadline indicated in Article I.5, the beneficiary shall submit a request for payment 
of the balance accompanied by the following documents: 
- a final report on the implementation of the action; 
- a final financial statement of the eligible costs actually incurred, following the structure of the 
estimated budget; 
- a full summary statement of the receipts and expenditure of the action; 
- where required by the provisions of Article I.4 on payment of the balance, a certificate on the 
action's financial statements and underlying accounts, produced by an approved auditor, or in 
case of public bodies by a competent and independent public officer. The certificate shall certify, 
in accordance with a methodology approved by the EMCDDA, that the costs declared by the 
beneficiary in the financial statements on which the request of payment is based are real, 
accurately recorded and eligible and that all receipts have been declared, in accordance with the 
agreement. 
The documents accompanying the request for payment shall be drawn up in accordance with the 
provisions of Article I.5 and the annexes. The beneficiary shall certify that the information provided in 
his request for payment is full, reliable and true. He shall also certify that the costs incurred can be 
considered eligible in accordance with the agreement, that all receipts have been declared, and that 
his request for payment is substantiated by adequate supporting documents that can be checked. 
On receipt of these documents, the EMCDDA shall have the period specified in Article I.4 in order to: 
- approve the final report on implementation of the action; 
- ask the beneficiary for supporting documents or any additional information it deems necessary to 
allow the approval of the report; 
- reject the report and ask for the submission of a new report.  
Failing a written reply from the EMCDDA within the time limit for scrutiny indicated above, the report 
shall be deemed to have been approved. Approval of the report accompanying the request for 
payment shall not imply recognition of their regularity or of the authenticity, completeness and 
correctness of the declarations and information they contain. 
If additional information or a new report is requested, the time limit for scrutiny shall be extended by 
the time it takes to obtain this information. The beneficiary shall be informed of that request and the 
extension of the delay for scrutiny by means of a formal document. The beneficiary shall have the 
period laid down in Article I.4 to submit the information or new documents requested.  




Extension of the delay for approval of the report may delay the payment by the equivalent time.  
Where a report is rejected and a new report requested, the approval procedure described in this 
article shall apply. 
In the event of renewed rejection, the EMCDDA reserves the right to terminate the agreement by 
invoking Article II.11.2(b). 
ARTICLE II.16 –GENERAL PROVISIONS ON PAYMENTS 
II.16.1 Payments shall be made by the EMCDDA in euro. Any conversion of actual costs into euro 
shall be made at the daily rate published in the Official Journal of the European Union or, 
failing that, at the monthly accounting rate established by the European Commission and 
published on its website applicable on the day when the payment order is issued by the 
EMCDDA, unless the Special Conditions of this agreement lay down specific provisions. 
Payments by the EMCDDA shall be deemed to be effected on the date when they are debited 
to the EMCDDA’s account. 
II.16.2 The EMCDDA may suspend the period for payment laid down in Article I.4 at any time  for the 
purposes of additional checks by notifying the beneficiary that his request for payment cannot 
be met, either because it does not comply with the provisions of the agreement, or because 
the appropriate supporting documents have not been produced or because there is a 
suspicion that some of the expenses in the financial statement are not eligible. 
 The EMCDDA may also suspend its payments at any time if the beneficiary is found or 
presumed to have infringed the provisions of the agreement, in particular in the wake of the 
audits and checks provided for in Article II.19. 
The EMCDDA may also suspend its payments: 
– if there is a suspicion of irregularity committed by the beneficiary in the implementation of 
the grant agreement; 
– if there is a suspected or established irregularity committed by the beneficiary in the 
implementation of another grant agreement or grant decision funded by the General 
Budget of the European Union or by any other budget managed by them. In such cases, 
suspension of the payments will only proceed where the suspected or established 
irregularity can affect the implementation of the current grant agreement. 
The EMCDDA shall inform the beneficiary as soon as possible of any such suspension by 
registered letter with advice of delivery or equivalent, setting out the reasons for suspension. 
Suspension shall take effect on the date when notice is sent by the EMCDDA. The remaining 
payment period shall start to run again from the date when a properly constituted request for 
payment is registered, when the supporting documents requested are received, or at the end 
of the suspension period as notified by the EMCDDA. 
II.16.3 On expiry of the period for payment specified in Article I.4, and without prejudice to paragraph 
2 of this Article, the beneficiary is entitled to interest on the late payment at the rate applied by 
the European Central Bank for its main refinancing operations in euros, plus three and a half 
points; the reference rate to which the increase applies shall be the rate in force on the first 




day of the month of the final date for payment, as published in the C series of the Official 
Journal of the European Union.  
Interest on late payment shall cover the period from the final date for payment, exclusive, up 
to the date of payment as defined in paragraph 1, inclusive. The interest shall not be treated 
as a receipt for the action for the purposes of determining the final grant within the meaning of 
Article II.17.4. The suspension of payment by the EMCDDA may not be considered as late 
payment. 
By way of exception, when the interest calculated in accordance with the provisions of the first 
and second subparagraphs is lower than or equal to EUR 200, it shall be paid to the 
beneficiary only upon demand submitted within two months of receiving late payment.  
II.16.4 The EMCDDA shall deduct the interest yielded by pre-financing which exceeds EUR 50 000 
as provided for in Article I.4 from the payment of the balance of the amount due to the 
beneficiary. The interest shall not be treated as a receipt for the action within the meaning of 
Article II.17.4.  
Where the pre-financing payments exceed EUR 750 000 per agreement at the end of each 
financial year, the interest shall be recovered for each reporting period. Taking account of the 
risks associated with the management environment and the nature of actions financed, the 
EMCDDA may recover the interest generated by pre-financing lower than EUR 750 000 at 
least once a year.  
Where the interest yielded exceeds the balance of the amount due to the beneficiary as 
indicated in Article II.15.4, or is generated by pre-financing referred to in the previous 
subparagraph, the EMCDDA shall recover it in accordance with Article II.18.  
Interest yielded by pre-financing paid to Member States is not due to the EMCDDA. 
II.16.5 The beneficiary shall have two months from the date of notification by the EMCDDA of the 
final amount of the grant determining the amount of the payment of the balance or the 
recovery order pursuant to Article II.17, or failing that of the date on which the payment of the 
balance was received, to request information in writing on the determination of the final grant, 
giving reasons for any disagreement. After this time such requests will no longer be 
considered. The EMCDDA undertakes to reply in writing within two months following the date 
on which the request for information is received, giving reasons for its reply. This procedure is 
without prejudice to the beneficiary’s right to appeal against the EMCDDA’s decision pursuant 
to Article I.8. Under the terms of Union law in this matter, such appeals must be lodged within 
two months following the notification of the decision to the applicant or, failing that, following 
the date on which the applicant learned of the decision. 
ARTICLE II.17 - DETERMINING THE FINAL GRANT 
II.17.1 Without prejudice to information obtained subsequently pursuant to Article II.19, the EMCDDA 
shall adopt the amount of the final payment to be granted to the beneficiary on the basis of 
the documents referred to in Article II.15.4 which it has approved. 
II.17.2 The total amount paid to the beneficiary by the EMCDDA may not in any circumstances 
exceed the maximum amount of the grant laid down in Article I.3.3, even if the total actual 
costs eligible exceed the estimated total eligible costs specified in Article I.3.2. 




II.17.3 If the eligible costs when the action ends are lower than the estimated total eligible costs, the 
EMCDDA’s contribution shall be limited to the amount obtained by applying the Union grant 
percentage specified in Article I.3.3 to the actual eligible costs approved by the EMCDDA. 
II.17.4 The beneficiary hereby agrees that the grant shall be limited to the amount necessary to 
balance the action’s receipts and expenditure and that it may not in any circumstances 
produce a profit for him. 
Profit shall mean any surplus of total actual receipts attributable to the action over the total 
actual costs of the action. The actual receipts to be taken into account shall be those which 
have been established, generated or confirmed on the date on which the request for payment 
of the balance is drawn up by the beneficiary for financing other than the Union grant, to 
which shall be added the amount of the grant determined by applying the principles laid down 
in paragraphs 2 and 3 of this article. For the purposes of this article, only actual costs falling 
within the categories set out in the estimated budget referred to in Article I.3.1 and contained 
in Annex II shall be taken into account; non-eligible costs shall always be covered by 
non-Union resources.  
Any surplus determined in this way shall result in a corresponding reduction in the amount of 
the grant. 
II.17.5 Without prejudice to the right to terminate the agreement under Article II.11, and without 
prejudice to the right of the EMCDDA to apply the penalties referred to in Article II.12, if the 
action is not implemented or is implemented poorly, partially or late, the EMCDDA may reduce 
the grant initially provided for in line with the actual implementation of the action on the terms 
laid down in this agreement. 
II.17.6 On the basis of the amount of the final payment determined in this way and of the aggregate 
amount of the payments already made under the terms of the agreement, the EMCDDA shall 
set the amount of the payment of the balance as being the amount still owing to the 
beneficiary. Where the aggregate amount of the payments already made exceeds the amount 
of the final grant, the EMCDDA shall issue a recovery order for the surplus. 
ARTICLE II.18 - RECOVERY 
II.18.1 If any amount is unduly paid to the beneficiary or if recovery is justified under the terms of the 
agreement, the beneficiary undertakes to repay the EMCDDA the sum in question on 
whatever terms and by whatever date it may specify. 
II.18.2 If the beneficiary fails to pay by the date set by the EMCDDA, the sum due shall bear interest 
at the rate indicated in Article II.16.3. Interest on late payment shall cover the period between 
the date set for payment, exclusive, and the date when the EMCDDA receives full payment of 
the amount owed, inclusive. 
Any partial payment shall first be entered against charges and interest on late payment and 
then against the principal. 
II.18.3 If payment has not been made by the due date, sums owed to the EMCDDA may be 
recovered by offsetting them against any sums owed to the beneficiary, after informing him 
accordingly by registered letter with advice of delivery or equivalent, or by calling in the 
financial guarantee provided in accordance with Article II.15.1. In exceptional circumstances, 
justified by the necessity to safeguard the financial interests of the Union, the EMCDDA may 




recover by offsetting before the due date of the payment. The beneficiary's prior consent shall 
not be required. 
II.18.4 Bank charges occasioned by the recovery of the sums owed to the EMCDDA shall be borne 
solely by the beneficiary. 
II.18.5 The beneficiary understands that under Article 299 of Treaty on the functioning of the  
European Union, the EMCDDA may adopt an enforceable decision formally establishing an 
amount as receivable from persons other than States. An action may be brought against such 
decision before the Court of First Instance of the European Union. 
ARTICLE II.19 – CHECKS AND AUDITS 
II.19.1 The beneficiary undertakes to provide any detailed information requested by the EMCDDA or 
by any other qualified outside body authorized by the EMCDDA for the purposes of checking 
that the action and the provisions of this agreement are being properly implemented. 
II.19.2 The beneficiary shall keep at the EMCDDA’s disposal all original documents, especially 
accounting and tax records, or, in exceptional and duly justified cases, certified copies of 
original documents relating to the agreement for a period of 5 years from the date of payment 
of the balance specified in Article I.4. 
II.19.3 The beneficiary agrees that the EMCDDA may have an audit of the use made of the grant 
carried out either directly by its own staff or by any other outside body authorized to do so on 
its behalf. Such audits may be carried out throughout the period of implementation of the 
agreement until the balance is paid and for a period of 5 years from the date of payment of 
the balance. Where appropriate, the audit findings may lead to recovery decisions by the 
EMCDDA. 
II.19.4 The beneficiary undertakes to allow EMCDDA staff and outside personnel authorised by the 
EMCDDA the appropriate right of access to sites and premises where the action is carried out 
and to all the information, including information in electronic format, needed in order to 
conduct such audits. 
II.19.5 By virtue of Council Regulation (Euratom, EC) No 2185/96 and Regulation (EC) No 1073/1999 
of the European Parliament and the Council, the European Anti-Fraud Office (OLAF) may also 
carry out on-the-spot checks and inspections in accordance with the procedures laid down by 
Union law for the protection of the financial interests of the European Union against fraud and 
other irregularities. Where appropriate, the inspection findings may lead to recovery decisions 
by the EMCDDA. 
II.19.6 The European Court of Auditors shall have the same rights as the EMCDDA, notably right of 










For the beneficiary     For the EMCDDA 
[name / forename]     Alexis GOOSDEEL 
[function]      Head of Unit  
 
 
Done at [place] on …/…/2011   Done at Lisbon on /…/2011 
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Annex 1 to the 2010 Reitox agreement 
Description of the action 
 
I. Introduction 
The National Focal Points (NFPs) are the main information interfaces between the MSs and the 
EMCDDA. It is their task, under Member State (MS) responsibility, to provide the EMCDDA with all 
information requested within the framework of the Centre’s work programmes (WPs) or to satisfy ad 
hoc requests from policy makers and other key partners of the EMCDDA. EMCDDA quality standards 
and deadlines have to be respected. NFPs are, together with the EMCDDA, responsible for a broad 
dissemination at national level of the EMCDDA and REITOX work results. 
At national level, each NFP should be the leading body that works closely together with all relevant 
partners that collect, produce and/or analyse data in the drugs field. NFPs should work closely 
together with scientists, policy-makers and specialists working in the field. They should closely follow 
and analyse the scientific, legal and policy developments in their countries. 
NFPs play an active role in the development process of the EMCDDA’s three-year WPs through the 
provision of comments and proposals on the objectives and the areas to be covered. They transform 
the EMCDDA WPs into national NFP-WPs and are responsible for the latter’s execution. NFPs are 
key partners in the conceptualisation of new key indicators and core data sets as well as in the 
improvement of the existing working areas. The quality level of the outputs of the NFPs and the 
EMCDDA is to a large extent determined by their active participation in the EU REITOX 
methodological working groups. 
The NFPs, under Member States’ responsibility, are responsible for: 
• collecting, harmonising and analysing national information according to EMCDDA standards 
and providing it to the EMCDDA; 
• monitoring and analysing national scientific, legal and policy developments; 
• coordinating and animating the national drug information network(s); 
• participating actively in the EMCDDA tasking processes; 
• executing the national REITOX WPs; 
• ensuring the production and dissemination of NFPs’ outputs nationally. 
The NFPs, under EMCDDA guidance, are responsible for: 
• cooperating in the improvement of existing EMCDDA working areas; 
• cooperating in the conceptualisation of new key indicators and core data sets; 
• language checking and proof-reading of EMCDDA products and publications; 
• broad dissemination at national level of the EMCDDA and REITOX outputs. 




II. Expected outputs for 2011 (for deadlines please refer to Annex III) 
The standard delivery expected from each NFP is determined by the ‘Operating framework of the 
Reitox System’, adopted by the Centre’s Management Board on 17 January 2003, as well as by the 
Centre’s three-year and annual WPs as well as by specific technical guidelines and time schedules. 
The NFPs participate in the development of all these fundamental documents. 
During the execution period of the present grant agreement for an action, each NFP (i.e. the 
beneficiary of the grant) is requested to produce the following output: 
1. Collection and analysis of information at national level in 2011: 
• Annual national report; 
• Statistical standard tables and structured questionnaires; 
• Data requested within the implementation of the epidemiological key indicators; 
• Data input into Scientific Based Research Information System and the REITOX extranet; 
• Council decision on information exchange, risk assessment and control of new psychoactive 
substances: early warnings to the EMCDDA; 
• Updates regarding national developments, e.g. operational, legal, institutional and political 
changes and events1; 
• Review process of national data contained in the EMCDDA draft annual report; 
• Press clippings covering major national developments as well as EMCDDA and/or NFP 
events, e.g. launch of the Annual Report¹ ; 
• Replies to ad hoc requests from the EMCDDA, through Reitox Coordination¹. 
2. Dissemination at national level: 
• Distribution of EMCDDA reports and other products; 
• Council decision on information exchange, risk assessment and control of new psychoactive 
substances: information from the EMCDDA to national partners; 
• Media relations at national level; 
• Informing relevant national partners and network(s) about quality feedback provided by the 
EMCDDA; 
• Responding to queries at national level or, where indicated, channelling such requests to the 
EMCDDA. Being the EMCDDA’s ‘ambassador’ at national level 2 ; 
• Language checking and proof-reading of EMCDDA products ²; 
3. Progress reports on the implementation of: 
The Council decision on information exchange, risk assessment and control of new psychoactive 
substances at national level. 
 4. Financial and contractual implementation reports : 
• Interim activity report on the implementation of the action between the start of the action until 
15 September 2011; 
                                                     
1
  When information requested is not readily available, the beneficiary is expected (within the limits of its 
resources’ availability) to make reasonable efforts to obtain this information. 
2
 The beneficiary is expected to make reasonable efforts in these particular areas, within the limits of its 
resources’ availability. 




• Interim financial implementation report, covering the period from the start date of the action 
until 15 September 2011; 
• Final activity report on the implementation of the action from the start date until 31 December 
2011; 
• Final financial implementation report, covering the period from the start date of the action until 
31 December 2011; 
• Full summary statement of the receipts and expenditure of the action; 
• Audit certificate established by a recognised (external) auditor of accounts. 
The beneficiary finally also commits him(her)self to participate in meetings and actions organised 
periodically by the EMCDDA, such as: Heads of REITOX Focal Points meetings, EU REITOX 
methodological meetings; ad hoc working parties, studies; surveys and pilot projects. 
